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ABSTRACT
Human pulmonary adenocarcinoma (PAC), which originates from bronchiolar
epitheliaVClara cells (PACC) or the alveolar type II cells (PAC type II), constitutes one
of the most rapidly rising lung cancer types. The occurrence of PAC in smoking and non
smoking individuals suggests that other factors besides smoking contribute to the
development and progression of PAC.

Earlier studies showed the presence of beta-adrenergic/cAMP growth pathway in PACC.
Consequently, beta-adrenergic stimulants in various drug formulations that are used in
the management of chronic respiratory diseases have been proposed as potential risk
factors for the development of PAC. On the other hand, little is known about the role of
this pathway in the proliferation of PAC type II. Using thymidine incorporation, this
study showed that the two PAC phenotypes have differential response to the beta
adrenergic/cAMP stimulation. Isoproterenol (broad-spectrum beta-adrenergic agonist)
and forskolin (adenylyl cyclase stimulator) induced significant proliferative response in
NCI-H322 cell line (PACC). Both beta-1 and beta-2 adrenergic receptors and cAMP are
involved in this proliferative response as shown by selective receptor and enzyme
inhibitors. On the other hand, A549 cells (PAC-type II) were inhibited by forskolin while
being unresponsive to beta-adrenergic stimulation. Accordingly, forskolin caused
significant and persistent activation of the extracellular signal regulated kinase (ERK.1/2)
in NCI-H322 cells in contrast to A549 cells, in which inhibition was observed.
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•
Cyclic AMP immunoassay of basal and stimulant-induced cAMP amount showed
marked difference between the two cell lines. The basal cAMP content in A549 cells was
significantly lower than that of NCI-H322 cells. Moreover, isoproterenol had no effect
while forskolin had significant but moderate rise of cAMP. By contrast, both
isoproterenol and forskolin induced a marked and significant accumulation of cAMP in
NCI-H322 cells.

In both cell lines, significantly higher proliferative response was observed in low serum
than in high serum culture condition. The epidermal growth factor receptor (EGFR)
mediated growth pathway is common to both cell lines as demonstrated by the use of
AG 1478 (EGFR-specific tyrosine kinase inhibitor). Furthermore, AG 1478 inhibited
isoproterenol but not forskolin-induced proliferation in NCI-H322 cells, implying the
existence of cAMP dependent and independent growth pathways and transactivation of
the EGFR.

The present study demonstrated an important difference between two cancer cell
phenotypes that are generally grouped as PAC. The implication of this distinction in
relation to cancer chemoprevention approaches and chronic management of respiratory
diseases with beta-adrenergic stimulants was emphasized. On the other hand, the EGFR
growth pathway is commonly expressed and plays a central role in the proliferation of
both PAC phenotypes. Consequently, the EGFR pathway may provide a common
chemotherapeutic target in broad family of cancer types and phenotypes with diverse
growth pathways.
Vl
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I.

INTRODUCTION

General Overview

It is estimated that around 1.3 million new cases of cancer will be diagnosed and
approximately half a million people will die from cancer in the United States in the year
2002 (Jemal et al., 2002). Besides, the total annual cost of cancer care in the United
States including direct and indirect costs has been estimated at more than $96 billion
(Schuette et al., 1995).

Lung cancer, which is one of the most common cancer types, has become a major
epidemic of the 20th century in the developed world from a very rare disease at the
beginning of the century (Janssen-Heijnen and Coebergh, 2001). It is the most frequently
diagnosed cancer type and the most common cause of cancer deaths in males and females
in the world. This trend is also expected to continue for many years to come (Travis et al.,
1996). Lung cancer mortality after 1950 may reflect the early impact of teenage cigarette
smoking on lung cancer risk in people under the age of 45 years (Jemal et al., 2001).
Unlike some types of cancers, lung cancer is usually diagnosed after metastasis and
acquisition of drug resistance (Malkinson, 2001). Despite improvement in diagnosis and
treatment, mortality rate is higher than 95% within 1 year of diagnosis (Parker, 1997;
Kane and Bunn, 1998).
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The four maJor pathological types of lung cancer are adenocarcinoma (35 -40%),
squamous cell carcinoma (25-30%), large cell carcinoma (10-15 %), and small cell lung
carcinoma (20-25 %). Because of their similar clinical behavior, adenocarcinoma,
squamous cell carcinoma, and large cell carcinoma are commonly grouped as non-small
cell lung cancer (NSCLC)(Kang et al., 2000).

Pulmonary adenocarcinoma is the fastest rising lung cancer type (Malkinson et al., 2000).
There has been a dramatic increase in the incidence of PAC in the last 10 to 15 years
(Wynder and Hoffmann, 1994; Hoffmann et al., 1997) and this trend is expected for a
wider geographical region in the near future. Janssen-Heijnen and Coebergh (2001)
predicted a worldwide increase in mortality from adenocarcinoma in contrast to
squamous cell carcinoma and small-cell carcinoma, for which a decrease is expected.
Adenocarcinoma may replace squamous cell carcinoma as the most frequent type of lung
cancer among men (Devesa et al., 1991). This trend has been largely attributed to deeper
inhalation after the introduction of filtered low tar cigarettes with consequent high
concentration of carcinogens in the peripheral airways (Wynder and Hoffmann, 1994;
Hoffmann et al., 1997). Consequently, the decrease in lung cancer mortality after 1990
due to the alleged long-term benefits of reductions in tobacco carcinogens in cigarettes
around 1960 (Jemal et al., 2001) might not apply to PAC. Moreover, PAC is common in
both smoking ancf non-smoking individuals implying that additional factors contribute to
the continued rise of this cancer type. Park et al. (1995) demonstrated a novel role of �
adrenergic mitogenic signal transduction in pulmonary Adenocarcinoma and Schuller et
al. (1999) showed that the tobacco-specific carcinogen NNK (4-(methylnitrosamino)-1-

2

(3-pyridyl)- 1 -butanone)) is a potent stimulator of this proliferative pathway. These
researchers pointed out that chronic treatment of existing respiratory diseases such as
asthma by beta-adrenergic stimulators might play a significant role in the PAC epidemic.
For instance, chronic obstructive pulmonary disease (COPD), which encompasses both
chronic bronchitis and emphysema, is one of the most common respiratory conditions of
adults in the developed world (Szelenyi and Marx, 200 1). The major clinical management
of COPD and other obstructive diseases utilizes the beta-adrenergic agonists or cAMP
elevating agents to relieve airway obstruction. The possible contribution of this
phenomenon to the spatial co-distribution of PAC and chronic respiratory diseases has
been suggested (Park et al., 1 995). In fact, various studies have shown that COPD
precedes lung cancer. Consequently, this association warrants that patients with COPD
should be monitored carefully for lung cancer (Weiss, 1 99 1 ). Such findings underlie the
necessity of characterizing the growth-regulating pathways in the various types of lung
cancers and identifying hitherto unknown risk factors. Moreover, assessment of the
presence of differential pathways would provide information on the applicability of such
risk factors across the major types of lung cancers.

Current cancer chemotherapy is mainly based on cytotoxic drugs and radiation. Narrow
safety margins and resistance has rendered several of the chemotherapeutic agents
ineffective (Ciardiello, 200 1), and chemotherapy of NSCLC is considered to have
reached its plateau of efficacy. This has made targeting pathways unique to these cancer
cells the best approach (Ferreira et al., 2002). Therefore, assessing the differential growth
pathways in the various NSCLC is deemed an important step towards this goal.
3

Cellular origin and physiology

Pulmonary adenocarcinoma (PAC) arises from the lung periphery and exhibits either
phenotypic feature of bronchiolar Clara cells (PACC) or alveolar type II cells (PAC-II).
Immunohistochemical evidence showed that about 50% of PAC expresses alveolar type
II phenotype whereas the remaining 50% exhibit Clara cell phenotype (Linnoila, 1 998)

Alveolar type II cells

The alveolar epithelium, which forms a lining of the alveolar spaces of the lung, consists
of alveolar type I and alveolar type II cells. Alveolar type I cells which constitute about
90% of the alveolar surface form most of the gas exchange surface. The alveolar type II
cells cover the remaining 1 0% of the alveolar surface (Sutherland et al., 200 1 ). Alveolar
type II cells differentiate and replace type I alveolar epithelial cells. Alveolar type II cells
are involved in the transportation of Na+ from the apical to the basolateral surface to
minimize excess alveolar fluid. This function, which is under beta-adrenergic control,
facilitates alveolar fluid clearance (Dumasius et al., 200 1 ).

Alveolar type II cells synthesize and secrete pulmonary surfactant that reduces the
surface tension and prevents alveolar collapse after expiration (Pian and Dobbs, 1 995 ;
Malkinson et al. , 1997). Surfactant secretion is regulated, among others, by a �4

adrenergic/cAMP pathway (Brown and Longmore, 1 98 1 ; Isohama et al., 200 1 ). Cyclic
AMP (cAMP, 3 ' : 5 '-cyclic adenosine monophosphate) increases the total amount of
saturated phosphatidylcholine, a lipid component of pulmonary surfactant, as well as the
incorporation of [ 3H] choline into surfactant phosholipid in a human lung cancer cell line
with phenotypic features of alveolar type II cells (A549) (Niles and Makarski, 1 979).
Smith ( 1 977) showed that adrenergic agents stimulated saturated phosphatidylcholine
secretion by A549 cells and that this was enhanced by cortisol. Smith (1 977) reported
that media that supported the most rapid rate of growth in A549 cells were least optimal
for saturated phosphatidylcholine synthesis. Saturated phosphatidylcholine production
was most efficient when growth was slow or arrested, whereas choline was incorporated
into unsaturated (structural) phosphatidylcholine when A549 cells were in an active
proliferative state. Cortisol-induced upregulation of B-adrenergic receptors with
subsequent differentiation and growth inhibition of A549 cells was also reported by
(Nakane et al. , 1 990). Unless there is a lung injury, most alveolar type II cells are in cell
cycle arrest. Proliferative and pathologic appearance of hyperplasic alveolar type II cells
is induced by growth factors including the epidermal growth factor (EGF) and
transforming growth factor-a (TGF-a) (Mason, 1 99 1 ). In summary, the �-adrenergic
signaling pathway may have a dual regulatory function in normal alveolar type II cells,
where it positively regulates many of the physiological processes while suppressing cell
proliferation.
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Clara cells

Clara cells and ciliated cells are the two mam functional cells of the bronchiolar
epithelium. The Clara cells, which are sometimes called the non-ciliated bronchiolar
secretory cells, are cuboidal to columnar epithelial cells lining the most distal conducting
airways (Plopper, 1 99 1 ). They are secretory cells and may be involved in mucus
production (Malkinson et al., 1997), a function that is under beta-adrenergic control.
Beta-adrenergic agonists such as isoproterenol and adrenalin and cAMP analogues
stimulate secretion whereas antagonists like propanolol inhibit it (Plopper, 199 1 ). Clara
cells can differentiate into mucin producing goblet cells. This differentiation is mediated
through non-proliferative epidermal growth factor receptor (EGFR) activation (Nadel,
200 1 ). This is in contrast with their tumorigenic counterparts where EGFR activation
induces cell proliferation (Schuller et al., 1994; Al Moustafa et al., 2002). Clara cells also
give rise to other Clara cells as well as ciliated cells. In steady state conditions, the
turnover of the Clara cell population is very low and less than 1 % of the cells incorporate
radiolabeled thymidine. Upon injury to bronchial epithelium, however, proliferation is
stimulated with more than 90% of the Clara cells incorporating radiolabeled thymidine
(Plopper, 199 1 ).

Clara cells have a high content of xenobiotic-metabolizing enzymes. Their active
detoxifying function may selectively expose Clara cells to cell inj ury or chemical
carcinogens such as nitrosamines, which are components of cigarette smoke
(Widdicombe, 1 982). The human pulmonary adenocarcinoma cell line with Clara cell
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phenotype, NCI-H322, metabolizes the polycyclic aromatic hydrocarbon benzo(a)pyrene
to various metabolites particularly to the reactive 7,8-diol-BP (Kiefer et al., 1 988).
Activated intermediates of phase-I metabolism, such as diol epoxides are electrophilic
carcinogens that covalently bind to DNA and other macromolecules (Annas et al., 2000).
Clara cells of rabbit origin have a lower DNA excision repair than alveolar type II cells,
suggesting an additional risk factor for mutation and subsequent malignant
transformation of these cells (Deilhaug et al., 1 985). Consequently, Clara cell� may serve
as the origin of distal airway tumors (Komaromy and Tigyi, 1 988).

Major growth regulating signaling pathways

The epidermal growth factor receptor (EGFR) ·

The EGFR signaling pathway demonstrates remarkable versatility in mediating a host of
signaling pathways that regulate diverse physiological and pathological processes. The
EGFR belongs to the family of Receptor Tyrosine kinases (RTKs ). The RTKs have
intrinsic enzymatic activity in the cytoplasmic region that is directed against the receptor
itself and downstream signaling molecules (Hubbard, 1 999). Most RTK ligands are
soluble polypeptide ligands including insulin, epidermal growth factor (EGF),
transforming growth factor-a (TGF-a), and platelet-derived growth factor (PDGF). The
RTKs are involved in a range of cellular physiology including fertilization, proliferation,
cell migration and apoptosis. In addition, they play key roles in various pathological
processes including cancer (Ostman and Bohmer, 200 1 ).
7

The EGFR is expressed in a variety of cell types and regulates a range of functions
including cell growth, differentiation, de-differentiation, and apoptosis, depending on the
context of density, type of matrix, and other cytokines (Wells, 2000); (Baselga, 2000).
The EGFR family consists of four closely related receptors namely the EGFR (erbB1),
erbB2 (HER2), erbB3 (HER3), and erbB4 (HER4). The EGFR (erbBl ) binds EGF, TGF
alpha, amphiregulin, heparin-binding EGF like growth factor, betacellulin, and
epiregulin. These ligands are synthesized as transmembrane precursors and are cleaved
by the matrix metalloproteases to be released as mature growth factors (Gschwind et al.,
2001).

EGFR (erbBl ) is a 170 KD glycoprotein composed of an extracellular ligand-binding
domain, a transmembrane domain, and an intracellular domain, which has Tyrosine
kinase activity (Hsieh et al., 2000). Binding of ligand to the monomeric EGFR, induces
EGFR dimerization, activation of intrinsic EGFR Tyrosine kinase activity, and
transphosphorylation of the dimerized receptor monomers (Maudsley et al., 2000).
Receptor autophosphorylation of Tyrosine residues out of the catalytic portion provides a
docking site for other signaling molecules via src homology-2 (SH2). Phospholipase C
(PLC), phosphatidylinositol 3-kinase (PI3K), growth factor receptor-bound protein 2
(GRB-2), and GTPase activating protein (GAP) are among the many signaling molecules
that use these docking sites to assemble signaling complexes (Nystrom and Quon 1999;
Hackel et al., 1999) (Figure 1)
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The Ras-mediated mitogen activated protein kinase (MAPK) cascade is one of the best
characterized signaling pathways initiated by activated EGFR. The Ras-mediated EGFR
MAPK cascade is initiated when the Grb-2 associated Sos (Ras guanine nucleotide
exchange factor) is recruited to phosphotyrosine residues of activated EGFR. This
association allows the formation of a complex that mediates the exchange of GTP for
GDP, hence activation of the small G protein Ras. This is followed by membrane
recruitment and activation of the serine-threonine kinase Raf (MAPK kinase kinase),
which in tum phosphorylates and activates MEK (MAPK kinase). The dual-specific
MEK (MAPK kinase) phosphorylates and activates the serine/threonine mitogen
activated protein kinases (MAPKs) (vanBiesen et al., 1 996; Maudsley et al., 2000).
Activated MAPK dimerizes and translocates to the nucleus to activate nuclear
transcription factors such as c-fos, c-jun, and c-myc that are involved in mitogenesis and
transformation (Lieberman et al., 1 996b ). The best-studied MAPKs are the extracellular
signal-regulated kinases (ERK1/p44mapK and ERK2/ p42mapK). Depending upon the
interacting signaling molecules, MAPKs mediate a range of cellular functions in the
membrane, nucleus, cytoplasm and cytoskeleton (vanBiesen et al., 1 996), eliciting a wide
array of responses such as cell division, differentiation, and secretion (Seger and Krebs,
1 995).

Besides the classical Ras-mediated kinase cascade, various signaling molecules could
also undergo phosphorylation and activation upon binding to phosphotyrosine residues on
activated EGFR. Activated Phospholipase C (PLC) hydrolyses membrane bound
phosphatidylinositol yielding diacylglycerol (DAG) and inositol phosphates (Graves and
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Lawrence, 1 996). Inositol phosphate regulates intracellular calcium, which together with
DAG, activates protein kinase C (PKC). Protein kinase C (PKC) causes potent activation
of ERK through the direct phosphorylation and activation of Raf-1 in a Ras-independent
manner (Kolch et al., 1 993 ). On the other hand, DAG can be metabolized to arachidonic
acid (AA), which in tum is metabolized by two enzyme families, the cyclooxygenases
(COX) and lipoxigenases (LOX), into metabolites that mediate various cellular functions,
including proliferation (Rao et al., 1 994; Liu et al., 2000).

Phosphatidylinositol 3 -kinase (PI3K) binds to phosphorylated Tyrosine residues of RTKs
(Stover et al., 1 995) and Shc-Grb2 (Saleem et al., 1 995) and catalyzes the
phosphorylation of inositol phospholipids (vanBiesen et al., 1 996). Phosphorylated
inositol phospholipids (Phosphatidylinositols) are required for the membrane localization
of phosphoinositide-dependent kinase (PDK). Membrane-localized phosphoinositide
dependent kinase (PDK) phosphorylates and activates protein kinase B (Akt), an enzyme
involved in cell proliferation and inhibition of apoptosis (Kim et al., 200 1 ). Recently,
Akt/PKB was identified as a promoter of cancer cell invasion through increased motility
and metalloproteinase production (Kim et al., 200 1 ). The requirement of PI3K for the
induction of DNA synthesis in quiescent cells was demonstrated by (Roche et al., 1 994).

Among the proteins that become phosphorylated by EGFR is the Janus kinase 1 (JAK 1 )
(Shual et al., 1 993) and the signal transducers and activators o f transcription (STAT)
(David et al., 1 996). Activated JAK phosphorylates STAT, which dimerizes and
translocates to the nucleus for gene activation (Shual et al., 1 993 ; Frank, 2002).
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Figure 1. Epidermal growth factor receptor-mediated growth signaling.
Classical RTKs such as the EGF receptor are single transmembrane domain
proteins. The cytosolic domain, which has an intrinsic kinase activity,
dimerizes and transphosphorylate (indicated as cross arrows) upon ligand
binding. Phosphorylated tyrosine residues serve as docking sites for
phosphotyrosine binding PTB or SH2 domain-containing adaptor proteins,
such as She and Grb2, and signaling molecules such as c-Src, phospholipase
Cy (PLCy), Ras.GTPase activating protein (GAP), and PBK. The various
docking molecules are then phosphorylated and activated to initiate a range
of signaling pathways. The exchange of Ras.GDP to the active Ras.GTP is
mediated by the Grb2-Sosl that is recruited to the activated EGF receptor
complex via She domain. Activated Ras activates Raf (MAPK kinase
kinase), which in tum phosphorylates and activates MEK (MAPK kinase) to
initiate the MAPK/ERK cascade. (Adapted from Luttrell et al. (1999).
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Activated EGFR also phosphorylates and activates STAT in a JAK-independent manner
(David et al., 1996)

The epidermal growth factor receptor and lung cancer

An autocrine growth loop 1s present when both the receptor and its ligand are
coexpressed in a cell with self-regulated proliferation (Tsao et al., 1996). Various
autocrine growth pathways have been associated with the pathogenesis of a variety of
cancers for which the EGFR has been implicated as a promoter of proliferation and
progression into malignant cells (Wells, 2000). Moreover, an internal autocrine
stimulation of the PDGF receptors with no need for growth factors has been found in v
sis transformed cells (Keating, 1988; Bejcek et al., 1989).

Several studies have shown that EGFR plays a major role in the autocrine growth of
human non-small cell lung cancer (NSCLC) (Liu and Tsao, 1993; Rusch et al., 1997).
The family of NSCLC is comprised of adenocarcinoma, squamous cell carcinoma, large
cell carcinoma and carcinoid (Kang et al., 2000). Expression and overexpression of
EGFR was found in a greater proportion of squamous and adenocarcinomas than in large
cell or small cell carcinoma (Rusch et al., 1993; Nakagawa, 2001). The co-expression of
transforming growth factor-a (TGF-a) and the EGFR exists in a range of lung cancer cell
lines particularly the NSCLC (Liu and Tsao 1993; Rusch et al., 1997; Hsieh et al., 2000).
These investigators reported TGF-a as the main and most important autocrine ligand in
NSCLC tumor formation. Moreover, activating point mutations of the Ras gene with
12

constitutively expressed mitogenic signals was observed m about 30% of NSCLCs
(Rodenhuis, 1 990).

EGFR overexpression is associated with reduced survival (Volm et al., 1 998; Nakagawa,
200 1), metastasis (Fontanini et al., 1 995), and resistance to chemotherapy (Dickstein et
al., 1 995) in lung cancer. Various chemotherapeutic approaches have targeted the EGFR
signaling pathway with encouraging preclinical results (Baselga, 200 1 ; Slichenmyer and
Fry, 200 1).

Signaling through the G protein-coupled receptors (GPCRs)

G protein-coupled receptors (GPCRs) are among the largest family of cell surface
receptors. They mediate signaling from a number of stimuli and ligands including peptide
and glycoprotein hormones, neurotransmitters, phospholipids, and photons. These
receptors consist of an extracellular ligand binding domain, a seven transmembrane
domain, and heterotrimeric G-proteins (vanBiesen et al., 1 996). The heterotrimeric G
protein consists of a, p, y subunits, which dissociate into active Ga-GTP and Gpy
subunits after interaction with ligand-bound receptor. Although there are numerous Ga
proteins, the main classes are the Gas, which activate adenylyl cyclase; the Gai, which
inhibit adenylyl cyclase; and Gaq, which activate phospholipase C. Besides the Ga
subunits, the Gpy-subunit is also involved in regulating various effectors, including
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adenylyl cyclase, phospholipase C and A2 isoforms, serine threonine kinases, and protein
kinase C (vanBiesen et al., 1 996) (Figure 2).

Adrenergic receptors, which are a group of GPCRs, are divided into a-ARs and P-ARs
based on functional and pharmacological characteristics. Activated P-adrenergic
receptors activate adenylyl cyclase through the stimulatory G-protein subunit (Gas ),
leading to cAMP synthesis (Ma and Huang, 2002). Cyclic AMP is an intracellular second
messenger that mediates actions of various physiological ligands and of beta-adrenergic
agonists. Elevation of cAMP influences cell physiology including proliferation, survival,
and differentiation, either stimulating or inhibiting the response depending on cell type
and context. Contradictory effects of cAMP might result from cellular specificities,
concentration, types, and localization of the cAMP-dependent protein kinases (PKA)
(Lange-Carter and Malkinson, 1991). There are nine isoforms of adenylyl cyclase
enzyme and the tissue specific expression of the specific isoforms determines the relative
amount of cAMP in response to stimuli (Daniel et al., 1 998). Moreover, the large number
of possible combinations of different G protein subunits and effector molecules allows
cells to respond in diverse ways (Lodish et al., 2000). Phosphodiesterase degrades cAMP
to 5 ' -adenosine monophosphate (5 ' -AMP) terminating the cAMP-mediated effect of
hormone stimulation.

Cyclic AMP activates protein kinase A (PKA), which phosphorylates numerous proteins,
with subsequent modulation of various cellular functions including gene transcription.
Gene transcription is mediated through the PKA-mediated activation of cAMP14

responsive transcription factors including cAMP-response-element-binding-protein
(CREB), cAMP-response-element-modulator (CREM), and activating-transcription
factor- 1 (ATF- 1 ) (Daniel et al., 1 998).

Most GPCR undergo four sequential steps to respond to stimulation by agonists. These
are activation, desensitization, internalization, and resensitization (Lefkowitz, 1 998).
Desensitization, which is a self-regulatory mechanism to responsiveness to agonists,
results when sites in the cytoplasmic domains are phosphorylated. In P-adrenergic
receptors, this phosphorylation creates a binding site for the SH2 domain of Src. After
Src is recruited, it phosphorylates and activates the G protein-coupled receptor kinase
(GRK), which in tum phosphorylates the receptor on serine and threonine residues,
creating a docking site for P-arrestin. Beta arrestin mediates the internalization of the
receptor through the formation of clathrin-coated pits. This process is necessary for
resensitization and redistribution of the receptors (Fan et al., 200 1 ).

Growth inhibitory signaling through the G protein-coupled receptors:In many cell types
cAMP, the ultimate effector of Gas, inhibits proliferation and serves as a counter
regulator of signals generated by growth factors such as the EGF and the platelet derived
growth factor (PDGF) and may reverse certain transformed cells to normal phenotypes
(Graves and Lawrence, 1 996). Cyclic AMP modulates receptor tyrosine kinase
dependent signaling pathways and subsequent biological responses (Mccawley et al.,
2000). This modulation of the EGFR-MAPK pathway occurs at various levels but is
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mainly mediated by the cAMP dependent protein kinase (PKA) (Graves and Lawrence,
1996).

Cyclic AMP-dependent inhibition of EGFR activation is cell type dependent. Inhibition
of the EGFR was reported in the human squamous cell carcinoma cells, A431 (Mitsui
and Iwashita, 1990; Iwashita et al., 1990). Similar effects on the insulin receptor have
been observed in lymphoblasts (Stadtmauer and Rosen, 1986). Barbier et al. (1999)
determined that cAMP was an inhibitor of EGF-induced activation of EGFR through a
serine phosphorylation of the receptor by PK.A. Consequently it was proposed that
activation of PKA would attenuate the EGFR Tyrosine kinase activity in a feedback
regulatory way. Nair and Patel (1993) and Barbier et al., (1999) showed that activation of
the adenylyl cyclase and subsequent increase in cAMP inhibited EGFR kinase activity in
the heart. In contrast, in some cell types, growth arrest by cAMP occurs without
inhibition of EGFR phosphorylation (Lieberman et al., 1996b). Likewise, the effect of
cAMP on MAPK activation is cell type dependent (Graves and Lawrence, 1996).

Protein kinase A phosphorylates RAF- I on specific serine residue, thereby interfering
with the ERK/MAPK cascade (Wu et al., 1993; Cook and McCormick, 1993). However,
the role of direct phosphorylation by PKA as the inhibitory mechanism is controversial
(Sidovar et al., 2000). Other works have demonstrated the inhibitory role of cAMP on
RAF-I in mouse fibroblast cells (Seger and Krebs, 19945; Piiper et al., 2000) but
different mechanisms of inhibition have been proposed. Protein kinase A inhibits
phospholipase C isotypes via phosphorylation of serine residue in human T cells (Park et
16

al., 1 992; Liu and Simon 1 996). Kim et al. (200 1 ) showed that cAMP inhibits the lipid
kinase activity of PB-K reducing the levels of phosphatidyinositols in mouse fibroblast
cells. This interferes with the membrane localization of phosphoinositide-dependent
kinase (PDK), which phosphorylates and activates protein kinase B (PKB/Akt).
Consequently, cAMP inhibits PKB/AKT-mediated outcomes, which includes prevention
of apoptosis (Cardone et al., 1 998). Cyclic AMP also inhibits the tyrosine
phosphorylation of JAK and STAT in myeloma cells (David et al., 1 996).

Beta-adrenergic stimulation induces apoptosis independent of PKA. Gu et al. (2000)
demonstrated a novel mechanism where Gas mediates apoptosis of S49 mouse
lymphoma cells through activation of Src family tyrosine kinase LcK, independent of
PKA. Similarly, the �-adrenergic receptor agonist, isoproterenol, induces apoptosis of
Gas-overexpressing cardiac myocytes (Geng et al. , 1 999). Isoproterenol inhibits MAPK
activation through the activation of Gas in simian fibroblast cells (Crespo et al., 1 995). In
summary, in many cell types, �-adrenergic receptor-mediated signaling antagonizes cell
proliferation and cell survival.

Mitogenic signaling through the G protein-coupled receptors:In contrast to the reports
summarized in the previous section, activation of the GPCRs also stimulates mitogen
activated protein kinase cascade that mediates cell growth or proliferation through
transcriptional regulation in many cell types. In cell types expressing this pathway,
GPCRs induce the activation of mitogenic signaling cascades associated with growth
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factor receptors in addition to the classical GPCR signaling pathway that results from the
dissociation of heterotrimeric G proteins and the generation of cAMP (Maudsley et al.,
2000). Stimulation of G protein-coupled receptors, including the beta-adrenergic
receptors, has been shown to have a mitogenic effect via the transctivation of the RTKs
(Luttrell et al., 1999; Maudsley et al., 2000). The activated RTK provides a structural
scaffold for assembly of mitogenic signaling complexes which containe many of the
same intermediates as those activated RTKs including: GPCR

➔

Grb2.mSOs

➔

Ras

➔

Raf

➔

MEK

➔ MAPK

➔ Tyrosine Kinase ➔ Sch

(Daaka et al., 1998; Luttrell et al.,

1999). Transactivation of RTK is associated with increased tyrosine autophosphorylation
and dimerization of EGFR and association with phosphorylated adapters (Luttrell et al.,
1997; Daub et al., 1997). The EGFR tyrosine kinase inhibitor, AG1478, abrogated the
mitogenic effect of GPCR stimulation, pointing to the obligatory role of RTK
transactivation in GPCR mitogenic pathways (Daub et al., 1996).

The mechanism of transactivation is not well understood although Gpy subunits, Src
kinases, and PKC have been mainly implicated (Luttrell et al., 1999). vanBiesen et al.
(1995) showed that Gpy subunit of Gi mediated the phosphorylation of She leading to
enhanced complex formation of the She, Grb2 and Sos, culminating in the activation of
the Ras/MAPK cascade. Other works have also shown the stimulatory role of Gpy for the
MAPK pathway (Faure et al., 1994; Luttrell et al., 1997b). Subsequent research indicated
that phosphatidylinositol-3-kinase (PI3-K) is an early intermediate upstream of Sos and
Ras in this Gpy-subunit-mediated MAPK activation (Hawes et al., 1996). Daub et al.

18

( 1 997) later showed that PB-K is required for MAPK activation but not for EGFR
transactivation. Luttrell et al. (1 996, 1 997), however, demonstrated that G�1-subunit
mediated the activation of Src (non-receptor tyrosine kinase), which in turn facilitated the
activation of She. Similarly, Chen et al. ( 1 994) showed activated Src was a propagator of
signals from the GPCRs to the RTK/MAPK cascade. In addition, Ma et al. (2000)
demonstrated a novel pathway in which Gai directly stimulated the c-Src. In support of
these findings, Simonson et al. (1 996) inhibited GPCR-mediated transcription of c-fos by
a dominant negative c-Src demonstrating the role of c-Src in GPCR-mediated cell growth
and development.

Many neurotransmitters and growth factors cause activation of PLC upon binding to
GPCR. The Gaq/I I class of Ga subunit directly activates PLC, which hydrolyses
membrane associated phosphatidylinositol to yield diacylglycerol (DAG) and inositol
phosphates. Inositol phosphates mediate elevated intracellular Ca++, which together with
DAG activates PKC (Wu et al., 1 992). PKC can directly activate Raf- 1 , initiating the
MAPK cascade in a Ras-independent manner (Kolch et al., 1 993).

G-protein coupled receptors (GPCRs) stimulate cell growth signaling in a Gas-dependent
manner. Maudsley et al. (2000) reported a novel pathway where isoproterenol stimulated
the EGFR pathway and the formation of a heterodimeric complex containing the B 2
adrenergic and EGFR receptors in simian fibroblast cells. Recently, a novel-signaling
pathway in which Gas stimulated the Src family tyrosine kinases in a cAMP-PKA
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independent fashion has been demonstrated in murine embryonic fibroblasts (Ma et al.,
2000). In contrast to its inhibitory effect on Raf- 1 , PKA activates the MAPK signaling in
a cell type specific manner (Schmitt and Stork, 2000). Faure et al. ( 1 994) had reported
earlier that constitutively activated Gas mutant, forskolin, and cAMP analogue increased
MAPK activation in simian fibroblast cells. Cyclic AMP-stimulated MAPK/ERK
activation also occurs in PC- 1 2 (pheochromocytoma cells of the adrenal gland) (Frodin et
al., 1 994; Vaillancourt et al., 1 994). This was attributed to the presence of Raf-1
independent and cAMP-insensitive pathway in some type of cells (Vaillancourt et al.,
1 994). Conversely, a recent finding showed that activation of ERK.1/2 by cAMP/PKA is
mediated through a distinct pathway involving Rap 1 (a Ras-related G-protein) and a cell
type specific isoform of Raf called Raf-B in lymphoma cells (Wan and Huang 1 998) and
PC- 1 2 cells (Vossler et al., 1997). Interestingly, this cAMP-mediated Raf-B activation is
accompanied by Raf- 1 inhibition (Vossler et al., 1 997). The activation of Rap l may be
PK.A-dependent or independent in a cell specific manner (Schmitt and Stork 2000).
Moreover, forskolin-induced cAMP activates GDP/GTP exchange factors called EPACs
(Exchange Protein directly Activated by cAMP) or cAMP-GEFs. These factors may
activate Rap 1 without any requirement of PK.A (de Rooij et al., 1 998; Kawasaki et al.,
1 998). Therefore, the expression of the B-raf determines whether cAMP inhibits or
stimulates the MAPK (ERK.1/2) (Gao et al., 1 999; Seidel et al., 1 999). In simian
fibroblast cells, Crespo et al. (1 995) demonstrated a signaling pathway from P-adrenergic
receptor where MAPK is activated and inhibited by Gpy and Gas subunits, respectively.
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They proposed these opposing regulatory pathways as a control mechanism of activation
of MAPK by the �-adrenergic receptors.

The transactivation of RTKs by GPCRs is a mitogenic pathway in some cancer cell lines.
EGFR transactivation by Gai subunit of GPCR with subsequent MAPK activation and
DNA synthesis occurs in astroglioma cells (Castagliuolo et al., 2000). Activating
mutations of the Gai subunit occurs in ovarian and adrenal neoplasms (Lyons et al.,
1 990). Moreover, transfection with constitutively active Gai transforms fibroblasts (Pace
et al., 1 99 1 ). Constitutive inhibition of adenyl cyclase hence relieving cAMP-mediated
inhibition of Raf- 1 and MAPK may explain the mitogenic effect of this mutant Gai
(vanBiesen et al., 1 996). Mutation of the Gas with a reduced intrinsic GTPase activity
occurs in pituitary and thyroid tumors (Lyons et al., 1 990). This creates a constitutively
activated GPCR with subsequent elevation of cAMP, which is mitogenic for many cell
types (Frodin et al., 1 994; Vaillancourt et al., 1 994).

In summary, GPCRs utilize multiple mechanisms to regulate cell growth. The pathway
that connects the GPCR to the MAPK signaling pathway is cell type-specific and
dependent on the type of receptor and associated G-proteins. Moreover, the availability,
the concentration, and the cellular localization of key signaling molecules probably also
play a key role in this cross interaction (Liebmann, 200 1 ).
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Ligand

Figure 2. G-protein coupled receptor-mediated growth signaling. The best
characterized MAPK that is activated by G-protein coupled receptors (GPCRs) is the
extracellular-regulated kinases (ERK.l /ERK2). This activation is mediated by different
classes of G proteins 1 ) Gas-mediated PKA-dependent activation of Raf depending on
the type of Raf. 2) Gag-mediated activation of protein Kinase C (PKC) that activates
Raf, hence MAPK and 3) G

�Y

and Src-mediated transactivation of receptor tyrosine

kinases with subsequent Ras/MAPK signaling 4. Gasmediated activation of Src,
which activates PI3k and She, with subsequent activation of the MAPK cascade.
Adapted from Liebmann (200 1 ).
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Beta-adrenergic signaling and cancer

The growth stimulatory and inhibitory effect of J3-adrenergic stimulation has been
documented in a range of cancer cell lines. Cyclic AMP inhibits growth and promotes
apoptosis in many cell types. In macrophages, Kato et al. ( 1 994) showed cAMP as an
inducer of p27kip 1 that inhibits cyclin D kinase-4 (CDK4), which is required for cell
cycle progression by cAMP. Various site-specific cAMP analogues have been identified
as cell cycle specific apoptotic agents in human lung carcinoma (Ally et al., 1 989) and
human neuroblastoma cells (Kim et al., 200 1 c).

Although limited, data on alveolar type II cells of human or mouse origin indicate that
cells of this phenotype are inhibited by cAMP-mediated mechanisms. Banoub et al.
( 1 996) showed the growth inhibitory effect of cAMP on mouse normal and neoplastic
alveolar type II cells. Growth inhibitory and differentiation promoting effect of
interleukin 1 (IL- 1 ) is associated with up-regulation of J3-adrenergic receptors in alveolar
type-II cells (Nakane et al., 1 990). Interestingly, some tumors of this phenotype are less
responsive to J3-adrenergic stimulation. Fewer beta-adrenergic receptors and diminished
cAMP production upon isoproterenol treatment was found in mouse alveolar type II
tumorigenic cells compared to their normal counterparts (Lange-Carter et al., 1 992).
Furthermore, mouse PACs of alveolar type II cell origin are deficient in cAMP
dependent protein kinase type I isozyme (PKA 1) compared to their non-tumorogenic
counterparts (Lange-Carter and Malkinson 1 99 1 ). However, PKAl messenger RNA
(mRNA) in the neoplastic alveolar cells is more stable, suggesting that the cause for low23

level PKA l results from transcriptional control (Lange-Carter and Malkinson 1 99 1 ). This
deficiency in PKA might lead to prolonged stimulation by the mitogenic Raf- 1 , which is
inhibited by PKA in small cell lung cancer cells (Schuller, 200 1 ) . Consequently,
neoplastic alveolar type II cells might have a proliferative advantage by evading negative
growth regulation from cAMP/PKA. In addition to these observations, Droms (1 996)
reported functionally uncoupled Gas but a functional adenylyl cyclase in neoplastic
mouse alveolar type II cells. Consequently, tumorigenic and normal alveolar type two
cells differed in isoproterenol-mediated, but not in forskolin-mediated, cAMP levels
(Droms, 1996). Dent et al. ( 1 998) reported that the total phosphodiesterase enzyme,
which is a cAMP catabolizing enzyme, is approximately nine-fold lower in human
bronchial epithelial cells than in the human PAC type II cell line A549. As a result, more
degradation of cAMP is expected in PAC cells of alveolar type II phenotype. In
summary, the P-adrenergic pathway negatively regulates proliferation while promoting
non-proliferative processes in alveolar type II cells. Consequently, it may be reasonable
to speculate that by down-regulating the number and function of the various P-adrenergic
effectors, alveolar type II cells gradually abandon their physiological role and assume an
uncontrolled proliferative state during their malignant transformation. This would
undoubtedly exacerbate the deteriorating alveolar physiology.

P-adrenergic signaling stimulates the growth of selected types of cancer types. This
signaling pathway enhances the growth of adenocarcinoma cell lines derived from the
human pancreas (Weddle et al., 200 1 ), lung (Schuller et al., 2000; Park et al., 1 995) or
breast (Cakir et al., 2002). Park et al. ( 1 995) initially demonstrated the mitogenic role of
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P-adrenergic signal transduction in human PAC of the Clara cell phenotype. This work
showed the importance of P-adrenergic agonists/cAMP in the proliferation of PAC.
Supporting data with an NNK-induced hamster PAC model showed that P-adrenergic
agonists promoted tumor development while P-adrenergic antagonists blocked this effect
(Schuller et al., 2000). Moreover, the tobacco-specific carcinogen, NNK, is a high
affinity agonist for P-adrenergic receptors (Schuller et al., 1 999). Exposure of human
PAC cell lines of Clara phenotype (NCI-H322 and NCI-H44 1 ) to these agonists resulted
in production of cAMP, release of AA, and DNA synthesis. These findings identified a
novel mechanism for tobacco-induced carcinogenesis. Schuller et al. ( 1 999) also
demonstrated the presence of B 1 and B2 receptors in PAC cell types. Consequently,
chronic treatment of respiratory diseases with P-adrenergic agonists may be a potential
risk factor for the increased incidence of PAC (Park et al., 1 995).

Finally, current data imply that PAC of Clara cell phenotype and PAC of alveolar type II
cell phenotype respond to elevated cAMP levels in an opposite manner. Agents affecting
the level of cAMP are expected to have antagonistic effects in the proliferation of PAC in
a phenotype-specific manner. The effect of P-adrenergic stimulation on proliferation of
EGFR expressing PAC cell lines is expected to be phenotype/cell type specific. This is
likely to have important clinical and epidemiological implications since beta-adrenergic
stimulators are active ingredients of drug formulations that are widely used in the
management of chronic respiratory diseases.
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Working hypothesis
• Pulmonary adenocarcinoma of Clara cell phenotype (PACC) and pulmonary
adenocarcinoma of alveolar type II cell phenotype (PAC type II) express an
EGFR autocrine growth pathway. This pathway is modulated by P-adrenergic
pathways in a cell-type specific and antagonistic manner.

Specific aims

1. Assess the presence of the epidermal growth factor receptor (EGFR)-mediated
proliferative pathway in human lung cancer cell lines of PACC and PAC-type II
phenotypes.
2.

Compare the effects of P-adrenergic stimulation and cAMP on proliferation of
PACC and PACC-type II cell lines.

3. Compare the basal and post-treatment levels of cAMP in PACC and PAC-type II
cell lines.
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MATERIALS AND METHODS

II.

Cells

Human pulmonary adenocarcinoma cell lines NCI-H322 (Clara cell phenotype) and
A549

(alveolar type II cell phenotype) (Giard et al., 1 973 ; Lieber et al., 1 976) were

obtained from the American Type Culture Collection (Rockville, MD). The cells were
grown in 75 cm2 vented cell culture flasks and routinely maintained in RPMI- 1 640
culture medium (Gibco) supplemented with fetal bovine serum (1 0%, v/v), L-glutamine
(2 mM), penicillin ( 1 00 U/ml) and streptomycin (100 mg/ml) (Gibco) at 37°C in an
atmosphere of 5% CO2 • All experiments were conducted with 1 - 1 2 passages.

Chemicals and biologicals

Isoproterenol (broad-spectrum beta-adrenergic agonist) and propanolol (broad-spectrum
beta-adrenergic blocker) (Sigma-Aldrich, St. Luis, Mo); Atenolol (selective beta 1
adrenergic blocker) and ICI- 1 1 8551 (selective beta 2 adrenergic blocker) {Tocris, UK);
AG1 478 (Selective EGFR Tyrosine kinase inhibitor), forskolin (adenylyl cyclase
stimulator),

PD98059

([2-(2' -amino-3 ' -methylphenyl)-oxanaphtalene-4-one])

(MEKl /MAPK Kinase 1 inhibitor), and SQ22536 (9-(tetrahydro-2-furanyl)- 9H-6-amine
(adenylyl cyclase inhibitor) (Calbiochem, La Jolla, CA); recombinant human epidermal
growth factor (rhEGF); anti beta-actin antibody; and biotynylated antibody against
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phosphotyrosine/clone PY-20 (Sigma-Aldrich, St. Louis, MO); human recombinant
transforming growth factor-a (rhTGF-a) and antibody against EGF (R & D systems,
Minneapolis, MN); antibody against the human EGF receptor; antibody against
phosphorylated mitogen activated kinase (anti Phospho-MAPK/ERK.1/2); horseradish
peroxidase (HRP)-lined anti-rabbit secondary antibody; HRP-linked anti-biotin antibody,
biotinylated molecular marker, and chemiluminescence horseradish peroxidase detection
kit (Cell Signaling Technology, Beverly, MA, Beverly, MA); [ 3H]-thymidine (specific
activity 82.0 Ci/mMol) (Amersham, UK).

[3H]-thymidine incorporation

General culture conditions for thymidine incorporation: [ 3H]-thymidine incorporation
was conducted to assess DNA synthesis and thus indirectly measure cell proliferation.
Cells grown to 60-70% confluency were trypsinized and 6 x 103 cells/well were plated
into 96 well plates in RPMI medium containing high-serum (10% FBS), L-glutamine (2
mM), penicillin (100 U/ml), and streptomycin (100 mg/ml). Cells were incubated for 24
hours in 37°C in an atmosphere of 5% CO2 • In this study, low-serum medium contained
RPMI-1640 tissue culture medium with 0.1 % fetal bovine serum (FBS) whereas high
serum medium contained RPMI-1640 tissue culture medium with 10% FBS. All
incubations for growth assay were done in low-serum containing [ 3H]-thymidine (0.5
µCi/well) and treatment agents or vehicle in a final volume of 200 µI/well for 24 hours in
37°C in an atmosphere of 5% CO2 • The amount of vehicle to dissolve the highest tested
concentration of treatment reagent was used for control groups. At the end of the
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specified incubation period, thymidine incorporation was assayed as described in the
subsequent section.

Modification of culturing conditions was done according to the type of assay. For growth
stimulation assays, the medium was changed to low-serum (0. 1 % FCS) for 24 hours to
starve cells, and then replaced by fresh low-serum medium. Agents that were used to
stimulate cell growth were recombinant human epidermal growth factor (rhEGF),
recombinant human transforming growth factor alpha (TGF-a), isoproterenol (broad
spectrum P-adrenergic agonist), and forskolin (adenylyl cyclase stimulator).

For growth inhibition assays, cells were treated in low-serum after the first 24-hr
incubation in high-serum. Agents used were antibody against EGF, AG1 478 (EGFR
specific Tyrosine kinase inhibitor), PD98059 (MEK inhibitor), and 8-Cl-cAMP (site
specific cAMP analogue). The site-specific cAMP analogue was used to test whether the
inhibitory effect of forskolin in A549 cells could be reproduced by cAMP.

Specific culture and treatment conditions for thymidine incorporation assay:
Recombinant human growth factor (rhEGF) was tested at 0 . 1 ng/ml, 1 ng/ml, 1 0 ng/ml,
20 ng/ml, 1 00 ng/ml, and 200 ng/ml. Acetic acid ( 1 0 mM in 0. 1 % BSA) was used as a
vehicle. Cells in the control group were treated with vehicle only.
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Recombinant human transforming growth factor-a (rhTGF-a) was tested at 20 ng/ml, 40
ng/ml, 100 ng/ml, and 200 ng/ml. Acetic acid (10 mM in 0. 1 % BSA) was used as a
vehicle. Cells in the control group were treated with vehicle only.

Antibody against the human epidermal growth factor was tested at 4 µg/ml, 8 µg/ml, and
16 µg/ml. The antibody was dissolved in the low-serum (0. 1 % FBS) culture medium.

The EGFR-specific tyrosine kinase inhibitor, AG1478, was tested at 1 µM, 10 µM, and
20 µM. Dimethyl sulfoxide (DMSO) was used as a vehicle. Cells in the control group
were treated with vehicle only.

The MEK l (MAPK kinase) inhibitor was tested at 1 µM, 10 µM, and 20 µM. Dimethyl
sulfoxide (DMSO) was used as a vehicle. Cells in the control group were treated with
vehicle only.

Isoproterenol (Broad-spectrum B-adrenergic agonist) was tested at 100 pM, 1 nM, 10 nM,
100 nM, and 1 µM. Isoproterenol was dissolved in the low-serum culture medium.

Forskolin (adenylyl cyclase stimulator) was tested at 100 pM, 1 nM, 10 nM, 100 nM, and
1 µM. Dimethyl sulfoxide (DMSO) was used as a vehicle. Cells in the control group were
treated with vehicle only.
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The site-specific cAMP analogue (8-Cl-cAMP) was tested at 0. 1 mM, 0.5 mM, and 1
mM. 8-Cl-cAMP was dissolved in the low-serum medium.

Preincubation with the various antagonists was done to verify specificity of the observed
isoproterenol-induced effects on DNA synthesis. At the end of the 24-hr starvation
period, cells were incubated for 20 minutes in a fresh low-serum medium containing
propanolol (broad-spectrum �-adrenergic antagonists, 2 µM), atenolol (selective � 1 aderenergic antagonist, 2 µM), ICI- 1 1 855 1 (selective �2-aderenergic antagonist, 2 µM),
or SQ22536 (adenylyl cyclase inhibitor, 2 µM). This pre-incubation was followed by the
addition of isoproterenol (2 µM) making the final concentration of isoproterenol and
antagonists 1 µM. Low-serum medium was used as a vehicle for isoproterenol
propanolol, atenolol, ICI- 1 1 855 1 whereas DMSO was used for forskolin and SQ22536.
Cells in the control groups were treated with vehicles only. Cells were incubated for an
additional 24 hrs, and DNA was harvested at the end of the incubation period. The
concentration used for specificity (1 µM) was adopted from earlier work from this
laboratory (Park et al., 1 995).

Preincubation with SQ22536 (adenylyl cyclase inhibitor) was done to verify the
specificity of the observed forskolin-induced effects on DNA synthesis. At the end of the
24-hr starvation period, cells were incubated for 20 minutes in a fresh low-serum medium
containing SQ22536 (2 µM). This pre-incubation was followed by the addition of
forskolin (2 µM) making the final concentration of forskolin and SQ22536 1 µM.
Dimethyl sulfoxide (DMSO) was used as a vehicle for both forskolin and SQ22536. Cells
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m the control group were treated with vehicle only. Cells were incubated for an
additional 24 hrs, and DNA was harvested at the end of the incubation period.

Preincubation with AG1478 (EGFR-specific Tyrosine kinase inhibitor) was done to
assess the involvement of the epidermal growth factor receptor in isoproterenol- and
forskolin-mediated effects on DNA synthesis. At the end of the 24-hr starvation period,
cells were incubated for 20 minutes in a fresh low-serum medium containing AG 1478 ( 1
µ M or 1 0 µM). This pre-incubation was followed by the addition of forskolin or
isoproterenol making the final concentration 1 µM. Low-serum medium was used as a
vehicle for isoproterenol whereas DMSO was used for forskolin and AG1478 . Cells in
the control group were treated with the vehicle only. Cells were incubated for an
additional 24 hrs, and DNA was harvested at the end of the incubation period.

In order to examine the effect of serum levels on DNA synthesis, cells were plated in
high-serum medium ( 10% FBS) and incubated for 24 hours. Cells then were rinsed with
low-serum medium (0. 1 % FBS) and fresh high-serum (10% FBS) or low-serum (0. 1 %
FBS) was added and incubated for 4, 8, 12, 18, and 24 hours. DNA was harvested at the
end of each incubation period.

DNA harvesting for thymidine incorporation assay: At the end of incubation period, cells
were washed 3 times with PBS and lysed by adding 30 µl of O. lN NaOH. The plate was
incubated at room temperature on a horizontal orbital microplate shaker. Incorporated
thymidine was selectively harvested from the lysates by vacuum filtration using a
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Micromate TM 1 96 cell harvester (Packard Instrument Company, Meriden, CT) onto a
backed glass fiber filter. The fiber was flushed with isopropanol (200µ1/well) to fix
adsorbed DNA. The harvester cut circular disks corresponding to each well. Each disk
was transferred to a scintillation vial containing 3 ml counting cocktail (Bio-Safe-IITM ,
Research Products International Corp., Mount Prospect, IL). A liquid scintillation
analyzer (Packard Instruments Company, Meriden, CT) was used to determine
radioactivity bound to the filters.

Thymidine incorporation assay for interrupted cultures in 24-well plates: The presence of
released growth factors in the low-serum growth condition was indirectly assessed using
the modified interrupted-culture-method (Murphy et al. 200 1 ). Cells (20 x 1 0 3 cells/well)
were plated in 24-well plates in high-serum and incubated for 24 hours. Cells were then
washed with low-serum and incubated in low-serum medium. In the first treatment group,
cells were continuously maintained for 48 hours without any interruption. In the second
treatment group, every 1 2 hours the medium was removed and cells were washed in-situ
with low-serum medium. Fresh low-serum medium was added and incubated. In the third
treatment group, every 1 2 hours the medium was removed and saved. Cells were washed
in situ with low-serum medium, and the saved primed medium was replaced. The third
treatment group served as a control for possible stress from frequent medium
manipulation. All treatment groups were maintained as described for 48 hours.

At the end of this period, medium was removed and cells were washed twice with low
serum. This was followed by addition of 0.5 ml of fresh low-serum medium containing
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[ 3H]-thymidine (0.5 µCi/well). After a 3 hours incubation, cells were washed 5X with
PBS. This was followed by precipitation with (1 :3) (v/v) solution of glacial acetic acid in
methanol for 1 0 minutes, and washed with 80% (v/v) methanol in water. DNA was
dissolved by adding of 0. lN NaOH (300 µl). The lysates were thoroughly mixed, and 1 00
µl of sample was transferred to a scintillation vial containing 3ml of counting cocktail. A
liquid scintillation analyzer was used to determine radioactivity.

Western blotting
To examine the effect of serum-starvation on MAPK expression, 5 x 1 05 cells were
plated in a 1 00 mm tissue culture dish and maintained in high-serum medium. At 70-80%
confluency, the medium was replaced with low-serum medium. Lysates for western
blotting were collected at 0, 1 5, and 30 minutes and 1 , 2, 8 and 1 2 hours incubation.

To assay the effects of treatment with forskolin (adenylyl cyclase stimulator) on MAPK
expression and activation, 5 x 1 05 cells were plated in RPMI- 1 640 medium supplemented
with 1 0% FBS in a 1 00 mm tissue culture dish. At 70-80% confluency, the medium was
replaced with low-serum medium (0. 1 % FBS) with or without forskolin. Lysates for
western blotting were collected at 0, 1 5 , and 30 minutes and 1 , 2, 8 and 1 2 hours
incubation. The same method was used to assess the effect of Ag1 478 (EGFR-specific
Tyrosine kinase inhibitor).
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At the end of each incubation period, cells were washed in situ with ice-cold phosphate
buffered saline (PBS). This was followed by lysis with 300 µl of RIPA [ cell lysis buffer
containing I XPBS, 1 %NP40, 0.5% sodium deoxycholate, 0. 1 % sodium dodecyl sulfate
(SDS)] including protease inhibitors [(1 0 µI/ml of 1 Omg/ml phenylmethylsulphonyl
fluoride (PMSF); 1 0 µI/ml of l OOmM sodium orthovanadate and 30µ1/ml of 1 .7 mg/ml
aprotinin)] . Cells then were scraped with a rubber policeman, transferred to a
microcentrifuge tube, and vortexed. The cell lysate was passed through a 2 1 -gauge needle
(2-3x); 1 0 µ1 of PMSF (1 Omg/ml) was added, and the mix was incubated on ice for 30
minutes. This was followed by centrifugation at 1 4,000 rpm (1 600 g's) for 20 minutes at
4 °C. The supemate was collected and the protein concentration was determined by
bichinchoninic acid assay (BCA™) (Pierce, Rockford, IL). A sample of cell lysate ( 1 0
µ1) was diluted to a final 1 : 1 0 concentration in RIPA buffer. Ten µl o f diluted lysate and
serial standard albumin preparation (0 to 1200 µg/ml) were added into 96 microplate
wells. To this was added 200-µl bichinchoninic acid reagent and incubated at 37°C for 30
minutes. Absorbance was read using a spectrophotometer (BioTeK Instruments Inc.,
Winooski, VT) at a wavelength of 550nm. Protein concentration (ug/ml) was determined
by linear regression (Graph Pad, San Diego, CA). A sample of lysate representing 20-µg
protein was used for electrophoresis. Each sample was mixed with an equal volume of
2X SDS (Sodium dodecyl sulfate) loading buffer (4% SDS, 0. 1 M Tris-Cl at pH 6.8,
0.2% bromophenol blue, 20% glycerol), centrifuged at high speed for 5 seconds, and
boiled for 3 minutes at 95 °C. Samples were then centrifuged at high speed for 5 seconds
and loaded onto a 1 0 % Tris-HCI PAGE gel (Bio-Rad Laboratories, Hercules, CA) and
subjected to 200 volts for 45 minutes in running buffer containing 1 0% of 1 OX Tris SDS
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buffer in deionized water. A biotin-labeled molecular weight marker (Cell Signaling
Technology, Beverly, MA) was run for each gel. Gels were removed and electrophoretic
transfer of proteins to nitrocellulose membrane was conducted at 1 00 volts for 1 hour in a
transfer buffer containing 5 . 8 g tris-hydroxymethyl-aminomethane, 2.9 g glycin, 3.7 ml
1 0% SDS, 200 ml methanol, and 800 ml deionized water. Membranes were removed and
washed three times (for 5 minutes each) with wash solution containing l X tris buffered
saline (TBS) (200 mM Tris HCl and 1 .5 M NaCl per liter) and 0.05% tween-20.
Membranes were blocked with 5% non-fat dry milk in lX TBS and 0.05% tween-20 for 1
hour. This was followed by three five-minute washes with wash solution. Membranes
were then incubated overnight at 4°C in primary antibody (rabbit polyclonal IgG for
phospho-ERKl /2, 200ug/ml) (Cell Signaling Technology, Beverly, MA) at a 1 : 1 000
dilution in the same blocking solution. The antibody against phospho MAPK (ERKl /2)
recognizes the phosphorylated Tyrosine and threonine residues at positions 204 and 202,
respectively (Cell Signaling Technology, Beverly, MA). At the end of the incubation
period, three five-minute washes were done. Membranes then were incubated for 1 hour
at room temperature in blocking solution containing horseradish peroxidase-linked
antirabbit IgG and horseradish peroxidase-linked antibiotin antibody at 1 :2000 and
1 : 1 000 dilutions, respectively. This was followed by three five-minute washes. Protein
bands were detected with a chemiluminescent horseradish peroxidase detection kit (Cell
Signaling Technology, Beverly, MA).

Equal loading of protein was ensured by stripping and incubating membranes with anti
actin polyclonal rabbit IgG in blocking solution at a dilution of 1 : 1 00. Membranes were
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stripped by incubation in a stripping buffer containing 36.5 ml deionized water, 1 0 ml
1 0% SDS, 350 µl mercaptoethanol ( l 00mM), 3 . 1 25 ml of tris HCl (pH 6.7, 62.5mM) for
45 minutes in a water bath at 50°C with gentle agitation. The same secondary antibodies
and procedure were used to detect protein bands.

lmmunoprecipitation and western blotting

Immunoprecipitation followed by western blotting was conducted to determine whether
the antiproliferative and MAPK inhibitory effect of forskolin, an adenylyl cyclase
stimulator, i� mediated through inhibition of EGFR phosphorylation. Cells were sampled
at 0 (no treatment), 30 minutes (maximal ERKl/2 activation), 8 hours (first highly
significant ERK 1/2 inhibition), and 24 hours (incubation length for thymidine
incorporation assay and last highly significant ERKl/2 inhibition). These sampling times
were selected to show modulation EGFR activation in relation to the ERKl/2 modulation
and DNA synthesis by forskolin.

Cells (5X 1 05) were plated in RPMI- 1 640 medium supplemented with 1 0% FBS in 1 00
mm tissue culture dishes. At 60- 70% confluency, the medium was replaced with low
serum (0. 1 % FBS) with or without forskolin. Harvesting of cell lysates was done at 0, 30
minutes, 8 hr and 24 hr as described for western blotting. At the end of each incubation
period, cells were washed with ice-cold PBS and cell lysate preparation and protein
determination was done as described for western blotting. A sample of lysate containing
400 µg protein was taken and 1 µg or 1 0 µl of 1 00 µg/ml rabbit anti-human EGFR
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antibody was added (Cell Signaling Technology, Beverly, MA). The mix was incubated
overnight at

4 °C with gentle rocking after which 20 uL (50% slurry) of Protein-A

beads (Santa Cruz, Santa Cruz, CA) was added and incubated for 4 hours at room
temperature with gentle rocking. This was followed by centrifugation at 2500 RPM ( 1 000
X g) for 5 minutes at 4 °C, and the supernate was carefully removed. The pellet was
washed five times by repeated centrifugation at 2500 RPM ( 1 000 X g) for 5 minute at 4
°C in 500 µl of RIPA ( cell lysis buffer) containing the same protease inhibitors and
concentrations indicated previously. Finally, 15 µl of RIPA with the protease inhibitors
was added followed by 15 µl of 2X loading/sample buffer to make a final volume of
30µ1. Samples then were centrifuged and heated to 95- 100 °C for 3 minutes as described
for the western blotting. Samples were finally centrifuged at high speed for 5 seconds to
homogenize the mix and then divided equally (15 ul/sample) and loaded on separate gels.
One of the gels was used to determine the total quantity of EGFR and the other one was
used to quantify the total amount of phosphorylated EGFR. A biotin-labeled molecular
weight marker was run for each gel. Electrophoresis of proteins and transfer to
nitrocellulose membranes were done as described for western blotting. After washing the
membrane as described earlier, membranes were blocked in 3 % bovine serum albumin
(BSA) for 1 hour. One of the membranes was then incubated with anti-rabbit polyclonal
antibody and horse radish peroxidase-linked antibiotin antibody at 1 :2000 and 1 : 1000
dilution in 3% BSA, respectively. Incubation was done for 1 hour at room temperature.
After washing the membranes as described earlier, protein bands were detected with a
chemiluminescent detection kit (Cell Signaling Technology, Beverly, MA). A molecular
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marker was used to detect the EGFR protein band. The other gel for detection of
phosphorylated EGFR was incubated with biotin

labeled monoclonal

anti

phosphotyrosine antibody (Clone PY-20) (Sigma-Aldrich, St. Louis MO) at 1 :5000
dilution in 3% BSA overnight at 4 °C with gentle rocking. The membrane was washed as
described earlier and blocked with 3% BSA. This was followed by the same washing
process and incubation with horse radish peroxidase-linked antibiotin antibody at a
1 : 1 000 dilution in 3% BSA for 1 hour at room temperature. Membranes then were
washed and protein bands were detected by chemiluminescent detection kit (Cell
Signaling Technology, Beverly, MA).

Densitometric analysis of protein bands

Densitometry of protein bands was done with a Scion image analyzer software (NIH,
Bethesda, MD). Densitometric values for target protein and beta-actin (internal control
protein) was expressed as pixel values. Relative expression of target proteins was
computed as ratio of pixel values of target protein/pixel values of beta-actin. Relative
quantity of phosphorylated EGFR in the immunoprecipitation assay was computed as a
ratio of pixel values of tyrosine-phosphorylated EGFR/pixel values of total EGFR.

Photography

Cells from both cell lines were plated (2 x 1 05/well) in 6-well tissue-culture plates in
high-serum medium and incubated at 37 °C for 24 hours. Medium then was replaced with
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fresh low-serum medium (0.1% FBS) containing rhEGF at increasing concentrations or
vehicle {l0 mM of acetic acid in 0.1% bovine serum albumin/BSA). Cells were then
incubated for 24 hours. Cells were examined with an inverted microscope and pictures
were taken with Nikon FX35A camera (Tokyo, Japan)

Cyclic AMP assay

The level of cAMP in cell lysates was determined with a cyclic AMP immunoassay kit
(R&D Systems, Minneapolis, MN).

Principle of the assay: The assay is based on the competitive binding technique in which
the cAMP present in a sample competes with a fixed amount of alkaline phosphatase
labeled cAMP for sites on a rabbit polyclonal antibody to cAMP. During the incubation,
the polyclonal antibody becomes bound to a goat anti-rabbit antibody coated on the
microplate. Following a wash to remove excess conjugate and unbound sample, a
substrate solution is added to the wells to determine the bound enzyme activity. The color
development is stopped after an hour of incubation and the absorbance is read at 405 nm.
The intensity of the color is inversely proportional to the concentration of cAMP in the
sample (R&D systems, Minneapolis, MN)

Cell culture, treatment and sample preparation for cAMP immunoassay: Cells
(4Xl0 5 /well) were plated in RPMI-1640 medium (10% FBS) in 6-well tissue culture
plates. Cells were incubated until they reached 70-80% confluence.
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Medium was removed and fresh RPMI- 1 640 medium (0. 1 % FBS) containing 1 mM 3isobutyl 1 -methylxanthine (IBMX), a phosphodiesterase inhibitor, was added to all
treatment and control groups. Cells were incubated for 30 minutes at 37 °C. To determine
control/basal cAMP levels, 4 wells from each cell line were washed three times with
distilled water and cells were incubated for 20 minutes in a 400 µl lysis solution
containing 0. l N HCl dissolved in 0. 1 % l 00X-Triton. The 0. 1 % l 00X-Triton was made in
l X TBS. Undetached cells were removed by repeated flushing with the cell lysate. Wells
were observed under a microscope to ensure complete removal of cells. The lysate was
transferred to centrifuge tubes. The wells then were washed with an additional 200 µl of
the lysis solution and this was added to the respective lysates. The cell lysates were
centrifuged at 600 g for 1 0 minutes at 4 °C. The supematants were collected and kept on
ice until analyed.

In the stimulation assays, isoproterenol ( 1 µM) or forskolin ( 1 µM or 1 0 µM) was added
after the medium containing IBMX was decanted, and cells were washed with low-serum
medium. Cells were then incubated for 20 minutes at 37 °C. At the end of incubation,
cells were harvested by the method described for the control groups.

In the inhibition assays, the medium containing IBMX was replaced with fresh low
serum medium containing ICI- 1 1 8-5 5 1 (selective P2-adrenergic antagonist) ( 1 µM) or
atenolol (selective P2-adrenergic antagonist) (1 µM). Cells were then incubated for 20
minutes, after which low-serum medium containing isoproterenol were added making the
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final concentration of isoproterenol 1 µM. Incubation was done at 3 7 °C for 20 minutes,
and cells were harvested for cAMP assay as described for the control groups.

In all cAMP assays, four additional wells for each cell line were used for determination
of protein concentrations/well . Plates for this purpose were harvested at the beginning of
the experiment with 200 µL RIP A containing protease inhibitor cocktail. The same
procedure of protein determination for lysate preparations described for western and
immunoprecipitation was employed. However, the lysates were diluted to 1 :2 instead of
1 : 10 to avoid over-dilution. Mean protein content (mg) of the four wells was used to
compute cAMP concentrations in pM/mg of protein.

Sample dilution for cAMP immunoassay: A sample of 1 25 µL was taken from the each
supemate. A 1 :2 dilution was made by adding 1 25 µL of asay buffer. This was mixed
well by vortexing and two 1 00-µL samples were taken for duplicate analysis.

Cyclic AMP standards for cAMP immunoassay: Serially diluted cAMP standards were
prepared at 200, 50, 1 2 .5, 3 . 1 25, and 0.78 1 pM/ml by diluting in the assay buffer
provided with the kit. Cyclic AMP standards were used within 30 minutes of preparation.

Assay procedure for cAMP immunoassay: Samples and standards were added to assay
wells at I 00 µL in duplicate. For the zero standard and non-specific binding (NSB) wells,
1 00 and 1 5 0 µL assay buffer was added, respectively. To all wells 50 µL of cAMP
conjugate (cAMP conjugated with alkaline phosphatase) was added. This was followed
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by the addition of 50 µL of cAMP antibody solution and incubation at room temperature
for 2 hours on a horizontal orbital microplate shaker set at 400 rpm. At the end of the
incubation period, medium was decanted and wells were washed 4 times with lX
washing buffer in distilled water. The plate was blotted to remove any remaining liquid.

For the measurement of total activity (TA), 5 µL of cAMP conjugate was added in two
additional wells. This was followed by the addition of 200 µL of substrate (p-nitrophenyl
phosphate) to all wells. The plate was then incubated for 1 hour at room temperature
without shaking. At the end of the 1 -hour incubation, 50 µL of stop solution (trisodium
phosphate) was added. Optical density was determined immediately using a
spectrophotometer set at 405 nm primary and 590 nm reference wavelengths (BioTeK
Instruments Inc., Winooski, VT).

Calculation of results: The duplicate readings for standards and samples were averaged.
The average reading from the non-specific binding wells (NSB) was subtracted from this
value. A dose response curve was generated by plotting the logarithm concentrations of
standards against respective mean absorbance using a non-linear regression curve fit (R2
= 0.9895 and 0.9995). The concentration of samples corresponding to the mean
absorbance was calculated in pM/ml from the dose-response curve (GraphPad Prism, San
Diego, CA). The total cAMP in the 600-µL-sample lysates then was determined. This
value was divided by the amount of total protein in the 600 µL to obtain the concentration
of cAMP in pM/mg.
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Statistical analysis

Graph Pad software was used to analyze data. Mean ± standard error of the mean of three
independent experiments with 4-8 replicates/group was generated for count per minute
(thymidine incorporation) and cAMP level. Mean values in control groups were set as
100% and values from treatment groups were normalized as percentage of values of
control groups. Two-way paired t-test was conducted to compare means between two
treatment groups. With more than two treatment groups, one-way analysis of variance
(ANOVA) was conducted with Dunnet comparison (comparison of mean of treatment
groups versus mean of the respective control group with treatment as the only fixed
effect). Basal cAMP content in the two cells was compared with unpaired t-test with
Welch's mean comparison for unequal variance. For comparison of the amount of protein
expression, computed target/internal-control pixel-ratios from independent experiments
were pooled and means were compared by one-way analysis of variance (ANOVA). The
level of significance (a-level) was set at 0.05.
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III.

RESULTS

Effect of serum level on proliferation

The effect of serum level on DNA synthesis was assessed by 3 H-thymidine incorporation
assay. In both cell lines, DNA synthesis was significantly higher in low-serum (0.1%
FBS) than in high-serum condition (10% FBS) (p<0.001). The stimulation was consistent
for all time intervals (Figure 3 and 4). A 48-hour low-serum incubation with replacement
of culture medium every 12 hours was conducted to indirectly assess the presence of
released growth stimulating factors in the serum. This caused significant (p<0.001)
reduction in DNA synthesis in both cell lines with a more pronounced effect in A549
cells (Fig 5 and 6). In order to rule out the effect of possible stress from repeated medium
replacement and rinsing, the procedure was conducted in a second control group with
some variation. The culture medium for this group was removed temporarily, and the
same medium was replaced. DNA synthesis was not significantly different from that of
the control group (p>0.05) (Figure 5 and 6).

A parallel increase in the level of phosphorylated or activated MAPK (ERKl /2) with
serum withdrawal was observed. Phosphorylated ERKl /2 content showed a significant
increase as early as 30 minutes after high-serum medium was replaced with low-serum
medium {P<0.05), a trend that was maintained at all sampling points in the 24-hour
period incubation in low-serum {P<0.01) (Figure 7 and 8).
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Figure 3. Effect of serum content on DNA synthesis in NCI-H322 cells
(P ACC). Cells were plated and incubated in high serum medium for 24
hours, after which fresh medium containing 1 0% FBS or 0. 1 % FBS with
[3 H]-thymidine (0. 5 µCi/well) was added. Cells were incubated for
additional 24 hours. Bars represent the mean CPM ± SE of each
treatment group from three independent experiments. Means in each
paired treatment groups were compared with paired-t test. Serum
deprivation significantly stimulated DNA synthesis (p<0.00 1 for all
incubation periods)
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Figure 4. Effect of serum content on DNA synthesis in A549 cells (PAC type II).
Cells were plated and incubated in high serum medium for 24 hours, after which
fresh medium containing 1 0% FBS or 0. 1 % FBS with [3H]-thymidine (0.5
µCi/well) was added. Cells were incubated for additional 24 hours. Bars represent
the mean CPM ± SE of each treatment group from three independent experiments.
Means in each paired treatment groups were compared with paired-t test. Serum
deprivation significantly stimulated DNA synthesis (p<0.001 for all incubation
periods)
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Figure 5 . Effect of continuous and interrupted culture on DNA synthesis in NCI-H322
cells (PACC). Cells were plated in 24-well plates in high serum medium and
incubated 24 hours. Fresh low serum medium was added to all wells. In control-1 , the
medium was continuously maintained without replacement. In control-2, every 12
hours, the primed medium was briefly removed, saved, and replaced immediately; In
the interrupted group, the primed medium was replaced with fresh low serum medium
every 12 hours. This treatment was done for 48 hours. At the end of the last 12-hr
incubation, 0.5 µCi [3H] -thymidine/well was added in fresh low serum medium and
incubated for 3 hours. Bars represent the mean CPM ± SE of each treatment group
from three independent experiments as percentage of mean value of the control-1
( continuous culture) group normalized as 100%. Means in each treatment group were
compared with the mean in the control group using ANOVA with Dunnet comparison.
Periodic replacement of primed medium with fresh medium significantly reduced
DNA synthesis. (ns - non significant/p>0.05 ;
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** - p<0.0 1 ; * - p<0.05 ; *** - p<0.00 1 )
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Figure 6. Effect of continuous and interrupted culture on DNA synthesis in A549
cells (PAC type-II). Cells were plated in 24-well plates in high serum medium and
incubated 24 hours. Fresh low serum medium was added to all wells. In control- I ,
the medium was continuously maintained without replacement. In control-2, every
1 2 hours, the primed medium was briefly removed, saved, and replaced
immediately; in the interrupted group, the primed medium was replaced with fresh
low serum medium every 1 2 hours. This treatment was done for 48 hours. At the end
of the last 1 2-hr incubation, 0.5 µCi [3 H]-thymidine/well was added in fresh low
serum medium and incubated for 3 hours. Bars represent the mean CPM ± SE of
each treatment group from three independent experiments as percentage of mean
value of the control- I (continuous culture) group normalized as 1 00%. Means in
each treatment group were compared with the mean in the control group using
ANOVA with Dunnet comparison. Periodic replacement of primed medium with
fresh medium significantly reduced DNA synthesis. (ns - non significant/p>0.05;
- p<0.01 ;

* - p<0.05; *** - p<0.00 1)
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Figure 7. Western blot of Phospho-MAPK showing the effect of serum
deprivation on activation of ERK.1/2 in NCI-A549 cells (PAC-type II). Cells
were plated and maintained in high serum medium until 70-80% confluency.
Medium then was replaced with low serum medium and cell lysates were
harvested at the indicated periods for western blotting. ERK.1 /2 was activated as
early as 30 minutes after high serum medium was replaced with low serum.
Actin bands serve as an internal control for equal protein loading.
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Figure 8. Densitometric values of western blot analysis showing the effect of
serum-deprivation on the amount of phospho-ERK.1/2 protein in A549 cells
(PAC type-II). Cells were plated and maintained in high serum medium until 7080% confluency. Medium then was replaced with low serum medium and cell
lysates were harvested at the indicated periods for western blotting. Bars
represent the mean ERK/actin pixel ratio as expressed as fold-increase of the
mean value of the control group (0 hr) that was normalized at 1 . Means in each
treatment group were compared with the mean from the control group using
ANOVA with Dunnet comparison. ERK.1 /2 was significantly activated as early
as 30 minutes after high serum medium was replaced with low serum. (ns -non
significant/p>0.05 ; * * - p<0.0 1 ; * - p<0.05 ; *** - p<0.00 1 ).
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Effect of TGFa, EGF and anti-EGF antibody on DNA synthesis
The effect of rhTGF-a (recombinant human transforming growth factor-a), rhEGF
(recombinant human epidermal growth factor), and antibody against the human
epidermal growth factor (EGF) on DNA synthesis was assessed by 3 H-thymidine
incorporation assay.

The human recombinant EGF had a differential effect on DNA synthesis in NCI-H322
and A549 cells. In A549 cells, EGF did not have any significant effect on DNA synthesis
at all concentrations tested (p>0. 05) (Figure 1 0). In contrast, except at lower
concentrations (� 1 0 ng/ml), EGF significantly increased DNA synthesis in NCI-H322
cells at 20ng/ml and higher concentrations (p<0.0 1 ) (Figure 9).

DNA synthesis was significantly inhibited by antibody against EGF in both cell lines.
Inhibition in NCI-H322 cells was significant (p<0.05) at 4 µg/ml and highly significant
(p<0.00 1 ) at 8 µg/ml and 1 6 µg/ml (Figure 1 2). The antibody against EGF also inhibited
DNA synthesis in A549 cells (Figure 1 3). However, the inhibitory effect of EGF
neutralization was less pronounced in this cell line as compared to that observed in NCI
H322 cells. Significant (p<0.05) inhibition was observed at 8 µg/ml and 1 6 µg/ml and no
significant (p>0.05) effect was observed at 4 µg/ml.

The human recombinant TGFa showed no significant effect on DNA synthesis in both
cell lines (p>0.05) (Figure 1 4 and 1 5).
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Effect of EGF on cell morphology
In A549 cells, EGF induced morphological changes ranging from spindle to multi
appendaged fibroblastic appearance. This effect was particularly evident at high EGF
concentration. This morphological change was not observed in NCI-H322 cells (Figure
1 1 ).

Effect of the tyrosine kinase inhibitor, AG1478, on DNA synthesis
The EGFR specific tyrosine kinase inhibitor, AG1 478 (Arteaga et al., 2002), invariably
inhibited DNA synthesis in both cell lines that was stimulated by serum deprivation.
Inhibition was highly significant at all concentrations used in NCI-H322 cells (p<0.00 1)
(Figure 1 6). Highly significant inhibition was also observed in A549 cells with exception
of 1 µM, which did not significantly affect DNA synthesis (p>0.05) (Figure 1 7). The
concomitant MAPK inhibition by AG1 478 was shown in A549 cells (Figure 1 8 and 1 9)

Effect of the MEKl inhibitor, PD98059, on DNA synthesis

The MEKl inhibitor, PD98059 (Dario et al., 1 995), inhibited DNA synthesis in both cell
lines as monitored by 3H-thymidine incorporation assay (Figures 20 and 1 6). Inhibition
was highly significant at all concentrations (p<0.00 1 ) with the exception of l µM, which
did not significantly affect DNA synthesis in A549 cells (p>0.05) (Figure 2 1 ).
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Figure 9. Effect of EGF on DNA synthesis in NCI-H322 cells (PACC). Cells
were plated and incubated in high serum medium for 24 hours. Medium was
replaced to low serum condition to starve cells for 24 hours. After the starvation
period, fresh low serum medium with 0.5 µCi [3 H]-thymidine/well containing
rhEGF or vehicle ( 1 0 mM acetic acid in 0. 1 % BSA). Cells were incubated for
additional 24 hours. Bars represent the mean CPM ± SE of each treatment group
from three independent experiments as percentage of mean value of the the
control group normalized as 1 00%. Means in each treatment group were
compared with the mean in the control group using ANOVA with Dunnet
comparison. EGF at � 20ng/ml significantly increased DNA synthesis. (ns - non
significant/p>0.05;

** - p<0.01 ; * - p<0.05; *** - p<0.00 1 )
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Figure 10. Effect of EGF on DNA synthesis in A549 cells (PAC type II). Cells
were plated and incubated in high serum medium for 24 hours. Medium was
replaced to low serum condition to starve cells for 24 hours. After the starvation
period, fresh low serum medium with 0.5 µCi [3H]-thymidine/well containing
rhEGF or vehicle (10 mM acetic acid in 0.1% BSA). Cells were incubated for
additional 24 hours. Bars represent the mean CPM ± SE of each treatment group
from three independent experiments as percentage of mean value of the control
group normalized as 100%. Means in each treatment group were compared with
the mean in the control group using ANOVA with Dunnet comparison. EGF
showed no significantly effect on DNA synthesis. (ns - non significant/p>0.05;
** - p<0.01; * - p<0.05;

*** - p<0.001)
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Figure 1 1 . Effect of EGF on cellular morphology. Epidermal growth factor differentially induced fibroblastic
morphology in A549 cells (PAC-type II)

N C I -H 3 2 2
1 2 0 ...... ·-··············-··-·-··--·-··-·····-·············-···-·- ····-·····-······-·······-·····-···-···-··-·-·······-······· .....
-

8 0 - ----·+ -

a.

60

· -·--- -

--

···· • • - · · · ···· ·· -·· ··· ·-----t

------· ·····--------····--·-·- -----·-------- ----- -

-- --

-- -------"* *·*--··-······-

***

-·······----·-··--··

c::::J C o n t r o l
- Anti- E G
a n tibody

40
20

--- · . · · -·· ··· · · - · ·- · ··-···· ···

0 .__._____..______
0
4

16

8
(µ g /m l]

Figure 1 2. Effect of anti-EGF antibody on DNA synthesis in NCI-H322 cells
(PACC). Cells were plated and incubated in high serum medium for 24 hours.
This was followed by the addition of low serum medium containing 0.5 µCi
[ 3 H]-thymidine/well with or without anti-EGF antibody was incubated 24
hours. Bars represent the mean CPM ± SE of each treatment group from three
independent experiments as percentage of mean value of the control group
normalized as 1 00%. Means in each treatment group were compared with the
mean in the control group using ANOVA with Dunnet comparison. Antibody
against

EGF

significantly
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DNA

synthesis.

significant/p>0.05; * * - p<0.0 1 ; * - p<0.05 ; *** - p<0.00 1 )
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Figure 1 3 . Effect of anti-EGF antibody on DNA synthesis in A549 cells
(PACC). Cells were plated and incubated in high serum medium for 24 hours.
This was followed by the addition of low serum medium containing 0.5 µCi
[ 3H]-thymidine/well with or without anti-EGF antibody was incubated 24
hours. Bars represent the mean CPM ± SE of each treatment group from three
independent experiments as percentage of mean value of the control group
normalized as 1 00%. Means in each treatment group were compared with the
mean in the control group using ANOVA with Dunnet comparison. Antibody
against EGF significantly but moderately decreased DNA synthesis at µ 8
ig/ml. (ns - non significant/p>0.05 ;
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** - p<0.0 1 ; * - p<0.05 ; *** - p<0.001 )
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Figure 1 4. Effect of TGF-a on DNA synthesis in NCI-H322 cells (PACC).
Cells were plated and incubated in high serum medium for 24 hours.
Medium was replaced to low serum condition to starve cells for 24 hours.
After the starvation period, fresh low serum medium with 0.5 µCi [3H]
thymidine/well containing rhTGF-a or vehicle ( 1 0 mM acetic acid in 0. 1 %
BSA). Cells were incubated for additional 24 hours. Bars represent the mean
CPM ± SE of each treatment group from three independent experiments as
percentage of mean value of the control group normalized as 1 00%. Means
in each treatment group were compared with the mean in the control group
using ANOV A with Dunnet comparison. TGF-a showed no significantly
effect on DNA synthesis. (ns - non significant/p>0.05;
p<0.05 ; *** - p<0.00 1 )

59

** -

p<0.01 ;

*-

A549
1 20 --- - - - - - -- -- -- - - - - - - - - - - - - - - - - ---- ---- - - --- - - - - - - - - ----- - - - - - - - - - - - - - - - - -------- - - - - -- -ns
1 00
� 80
�
u

c:J Control

60

- TGFa

40 - - - - - - - - - - - - - - - - - - - - - - 20 --- --------------------

o._.___.______
0

20

40

1 00

200

[ng/ml]

Figure 1 5. Effect of TGF-a on DNA synthesis in A549 cells (PAC type11). Cells were plated and incubated in high serum medium for 24 hours.
Medium was replaced to low serum condition to starve cells for 24 hours.
After the starvation period, fresh low serum medium with 0.5 µCi [3H]
thymidine/well containing rhTGF-a or vehicle ( 1 0 mM acetic acid in 0. 1 %
BSA). Cells were incubated for additional 24 hours. Bars represent the
mean CPM ± SE of each treatment group from three independent
experiments as percentage of mean value of the control group normalized
as 1 00%. Means in each treatment group were compared with the mean in
the control group using ANOVA with Dunnet comparison. TGF-a showed
no significantly effect on DNA synthesis. (ns - non significant/p>0.05;
p<0.0 1 ;

* - p<0.05; *** - p<0.00 1 )
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Figure 1 6. Effect of the EGFR-specific tyrosine kinase inhibitor, AG 1478,
on DNA synthesis in NCI-H322 cells (PACC). Cells were plated and
incubated in high serum medium for 24 hours. This was followed by the
addition of low serum medium with 0.5 µCi [3 H]-thymidine/well
containing AG1 478 or vehicle (DMSO). Cells were incubated for
additional 24 hours. Bars represent the mean CPM ± SE of each treatment
group from three independent experiments as percentage of mean value of
the the control group normalized as 1 00%. Means in each treatment group
were compared with the mean in the control group using ANOVA with
Dunnet comparison. AG1478 significantly reduced DNA synthesis. (ns non significant/p>0.05;

** - p<0.0 1 ; * - p<0.05; *** - p<0.00 1 )
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Figure 17. Effect of the EGFR-specific tyrosine kinase inhibitor, AG1478,
on DNA synthesis in A549 cells (PAC-type II). Cells were plated and
incubated in high serum medium for 24 hours. This was followed by the
addition of low serum medium with 0.5 µCi [3 H]-thymidine/well
containing AG1478 or vehicle (DMSO). Cells were incubated for
additional 24 hours. Bars represent the mean CPM ± SE of each treatment
group from three independent experiments as percentage of mean value of
the control group normalized as 100%. Means in each treatment group
were compared with the mean in the control group using ANOV A with
Dunnet comparison. AG1478, except at l iM, significantly reduced DNA
synthesis that was stimulated by serum deprivation. (ns - non
significant/p>0.05 ;

** - p<0.01; * - p<0.05; *** - p<0.001)
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Figure 1 8. Western blot of Phospho-MAPK showing the effect of the EGFR
specific tyrosine kinase inhibitor, AG 1478 (l OiM) on ERKl /2 activation in
NCI-A549 cells (PAC-type II). Cells were plated and maintained in high serum
medium until 70-80% confluency. Medium was then replaced with low serum
medium containing AG 1 4 78 ( 1 0 µM) and incubated for the indicated periods.
At the end of the respective incubation period, cells were harvested for western
blot analysis. Inhibition of ERKl /2 activation was evident as early as 1 5
minutes with complete inhibition at 24 hours. Actin bands serve as an internal
control for equal protein loading.
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Fig 19. Densitometric values of western blot analysis showing the effect of
AG 1478 (EGFR-specific tyrosine kinase inhibitor) on the amount of
phospho-ERK.1 /2 protein in A549 cells (PAC type-II). Cells were plated and
maintained in high serum medium until 70-80% confluency. Medium was
then replaced with low serum medium containing AG 1478 (10 µM) and
incubated for the indicated periods. At the end of the respective incubation
period, cells were harvested for western blot analysis. Bars represent the
mean ERK/actin pixel ratio as a percentage of the mean value of the control
group (0 hr), which was normalized at 1 00%. Means in each treatment group
were compared with the mean from the control group using ANOVA with
Dunnet comparison. AG1478 induced significant inhibition of ERK.1 /2
activation as early as 15 minutes. (ns -non significant/p>0.05;
- p<0.05 ;

*** - p<0.00 1).
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Figure 20. Effect of the MEK (MAPK Kinase) inhibitor, PD98059, on
DNA synthesis in NCI-H322 cells (PACC). Cells were plated and
incubated in high serum medium for 24 hours. This was followed by the
addition of low serum medium with 0.5 µCi [3H]-thymidine/well
containing AG1 478 or vehicle (DMSO). Cells were incubated for
additional 24 hours. Bars represent the mean CPM ± SE of each treatment
group from three independent experiments as percentage of mean value of
the control group normalized as 1 00%. Means in each treatment group
were compared with the mean in the control group using ANOVA with
Dunnet comparison. PD98059 significantly reduced DNA synthesis. (ns non significant/p>0.05 ;

** - p<0.0 1 ; * - p<0.05; *** - p<0.00 1 )
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Figure 2 1 . Effect o f the MEK (MAPK Kinase) inhibitor, PD98059, on
DNA synthesis in A549 cells (PAC type II). Cells were plated and
incubated in high serum medium for 24 hours. This was followed by the
addition of low serum medium with 0.5 µCi [ 3 H]-thymidine/well
containing AG1 478 or vehicle (DMSO). Cells were incubated for
additional 24 hours. Bars represent the mean CPM ± SE of each treatment
group from three independent experiments as percentage of mean value of
the control group normalized as 1 00%. Means in each treatment group
were compared with the mean in the control group using ANOV A with
Dunnet comparison. PD98059, except at 1 µM, significantly reduced
DNA synthesis that was stimulated by serum deprivation. (ns - non
significant/p>0.05 ;

** - p<0.0 1 ; * - p<0.05 ; *** - p<0.00 1 )
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Effect of the beta-receptor agonist (lsoproterenol), and the adenylyl cyclase stimulator
(Forskolin) on DNA synthesis
3

H-thymidine incorporation assays with isoproterenol (� 1 and �2 agonist) and forskolin

(adenylyl cyclase stimulator) had differential effects on DNA synthesis in NCI-H322
(Figures 22 and 24, respectively) and A549 cells (Figures 23 and 25, respectively).
Isoproterenol induced highly significant stimulation of DNA synthesis in NCI-H322 cells
at all concentrations used ( 1 00 pM to l uM) (p<0.0 1 - P<0.00 1 ). Higher concentrations
( 1 0 µM and 20 µM) were toxic to both cell lines. The proliferative effect of isoproterenol
was significantly blocked (P<0.00 1 ) by pre-incubation with 1 µM of propanolol (broad
spectrum beta-adrenergic antagonist) (Figure 33), atenolol (selective beta- I adrenergic
antagonist) (Figure 36), ICI- 1 1 85 5 1 (selective beta-2 adrenergic antagonist) (Figure 36),
or SQ22536

(the adenylyl cyclase inhibitor) (Figure 33). Similar blockage of

isoproterenol-induced proliferation was observed with pre-incubation with 1 µM of
AG1 478 (EGFR-specific tyrosine kinase inhibitor) (P<0.00 1 ). Pre-incubation with 1 0 µM
of AG 1 478 blocked both forskolin-induced and basal DNA synthesis in low-serum
condition (P<0.00 1 ) (figure 35).

Similarly, the adenylyl cyclase stimulator, forskolin, caused a highly significant
stimulation of DNA synthesis in NCI-H322 cells at 1 µM (p<0.00 1 ) (Figure 24). Lesser
concentrations did not have any significant effect (P>0.05). The proliferative effect of
forskolin (1 µM) was completely blocked by pre-incubation with the adenylyl cyclase
inhibitor, SQ22536 ( 1 µM) (P<0.00 1 ) (Figure 33). Forskolin-induced DNA synthesis was
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not blocked by 1 µM AG1478 (P>0.05). However, AG1478 at 10 µM blocked both
forskolin-induced and basal DNA synthesis (P<0.001) (Fig 35).

By contrast, isoproterenol had no si gnificant effect on DNA synthesis in A549 cells at all
tested concentrations (p>0.05) (Figure 23). Contrary to its effect on NCI-H322 cells,
forskolin caused si gnificant inhibition of DNA synthesis in A549 cells (p<0.05) (Figure
25).

This inhibitory effect was si gnificantly but not completely blocked by pre

incubation of with 1 µM of SQ22536 (P<0.01) (Fig 34).

Effect of the cAMP analogue, 8-chloro-cAMP, on DNA synthesis

The site-specific, cell-permeable cAMP analogue, 8-chloro-cAMP, significantly inhibited
DNA synthesis at all concentrations tested (P<0.01) (Figure 26).

Effect of Forskolin on activation of MAPK

Treatment with 10 µM forskolin had a differential effect on the activation of ERK.1/2 in
A549 and NCI-H322 cells. A highly significant activation of ERK.1/2 was evident as
early as 15 minutes in NCI-H322 cells, which was maintained throughout the sampling
points, with the highest phospho-ERK.1/2 quantity observed at 24 hours (P<0.05 P<0.001) (Figure 27 and 28).
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On the other hand, forskolin caused an early activation and subsequent inhibition of
MAPK (ERKl/2) in A549 cells (Figure 29 and 30). An early and si gnificant stimulation
was observed as early as 1 5 minutes (P<0.00 1 ). The highest ERKl/2 activation (based on
our sampling time) was observed at 30 minutes. This was followed by a consistent
decline with si gnificantly lower quantity (about 75% of control) observed at 8 and 24
hours (P<0.00 1 ).

Effect of the adenylyl cyclase stimulator, forskolin, on EGFR
phosphorylation

The quantity of phosphorylated EGFR was not si gnificantly affected by forskolin ( 1 0
µM) at 30-minutes and 8-hours (Figure 3 1 and 32). The amount of phospho-EGFR in the
0-hr control group was significantly higher than that was found in the 24-hr forskolin
treatment group (P<0.05). Likewise, the amount of Phospho-EGFR in the 24-hr control
group was si gnificantly higher than that was found in the 24-hr forskolin treatment group
(P<0.05). However, there was also a si gnificant increase in the amount of phospho-EGFR
during the 24-hour incubation period in the control group (P<0.05).
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Figure 22. Effect of the broad-spectrum P-adrenergic agonist, isoproterenol, DNA
synthesis in NCI-H322 cells (PACC). Cells were plated and incubated in high
serum medium for 24 hours. Medium was replaced to low serum condition to
starve cells for 24 hours. After the starvation period, fresh low serum medium
containing 0.5 µCi . [3 H]-thymidine/well with or without isoproterenol. Cells were
incubated for additional 24 hours. Bars represent the mean CPM ± SE of each
treatment group from three independent experiments as percentage of mean value
of the control group normalized as 100%. Means in each treatment group were
compared with the mean in the control group using ANOVA with Dunnet
comparison. Isoproterenol significantly stimulated DNA synthesis. (ns - non
significant/p>0.05 ;

** - p<0.01; * - p<0.05 ; *** - p<0 .001)
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Figure 23 . Effect of the broad-spectrum �-adrenergic agonist, isoproterenol,
DNA synthesis in A549 cells (PAC type II). Cells were plated and incubated in
high serum medium for 24 hours. Medium was replaced to low serum
condition to starve cells for 24 hours. After the starvation period, fresh low
serum medium containing 0.5 µCi [3H]-thymidine/well with or without
isoproterenol. Cells were incubated for additional 24 hours. Bars represent the
mean CPM ± SE of each treatment group from three independent experiments
as percentage of mean value of the control group normalized as 1 00%. Means
in each treatment group were compared with the mean in the control group
using ANOVA with Dunnet comparison. Isoproterenol showed no significant
effect on DNA synthesis. (ns - non significantlp>0.05 ;
*** - p<0.00 1 )
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Figure 24. Effect of the adenylyl cyclase stimulator, forskolin, on DNA
synthesis in NCI-H322 cells (PACC). Cells were plated and incubated in
high serum medium for 24 hours. Medium was replaced to low serum
condition to starve cells for 24 hours. After the starvation period, fresh
low serum medium with 0.5 µCi [ 3H] -thymidine/well containing
Forskolin or vehicle (DMSO) was added. Cells were incubated for
additional 24 hours. Bars represent the mean CPM ± SE of each treatment
group from three independent experiments as percentage of mean value of
the control group normalized as 1 00%. Means in each treatment group
were compared with the mean in the control group using ANOVA with
Dunnet comparison. Forskolin at 1 µM significantly stimulated DNA
synthesis (ns - non significant/p>0.05;
p<0.00 1 )
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Figure 25. Effect of the adenylyl cyclase stimulator, forskolin, on DNA synthesis
in A549 cells (PAC type-II). Cells were plated and incubated in high serum
medium for 24 hours. Medium was replaced to low serum condition to starve cells
for 24 hours. After the starvation period, fresh low serum medium with 0.5 µCi
[ 3 H]-thymidine/well containing Forskolin or vehicle (DMSO) was added. Cells
were incubated for additional 24 hours. Bars represent the mean CPM ± SE of
each treatment group from three independent experiments as percentage of mean
value of the control group normalized as 1 00%. Means in each treatment group
were compared with the mean in the control group using ANOVA with Dunnet
comparison. Forskolin at � 1 0 nM significantly inhibited DNA synthesis. No
significant cytotoxicity was observed with trypan blue exclusion assay (ns - non
significant/p>0.05 ;

** - p<0.01 ; * - p<0.05 ; *** - p<0.00 1 )
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Figure 26. Effect of the site-specific cAMP analogue, 8-Chloro-cAMP, on
DNA synthesis in A549 cells (PAC type II). Cells were plated and
incubated in high serum medium for 24 hours. This was followed by the
addition of low serum medium containing 0.5 µCi [3 H] -thymidine/well with
or without 8-chloro-cAMP . Cells were incubated for additional 24 hours.
Bars represent the mean CPM ± SE of each treatment group from three
independent experiments as percentage of mean value of the control group
(low serum medium) normalized as 1 00%. Means in each treatment group
were compared with the mean in the control group. Means in each treatment
group were compared with the mean in the control group using ANOVA
with Dunnet comparison. 8-Chloro-cAMP significantly reduced DNA
synthesis. (ns - non significant/p>0.05 ;
p<0.00 1 )
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Figure 27. Western blot of Phospho-MAPK showing the effect of the adenylyl
cyclase stimulator, forskolin on ERK.1/2 activation in NCI-H322 cells (PACC).
Cells were plated and maintained in high serum medium until 70-80%
confluency. Medium was then replaced with low serum medium containing
forskolin ( 1 0 µM) and incubated for the indicated periods. At the end of the
respective incubation period, cells were harvested for western blot analysis.
Activation of ERK.1/2 was evident as early as 30 minutes after treatment.
Activation was maintained through out the 24-hour incubation period. Actin
bands serve as an internal control for equal protein loading.
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Fig 28. Densitometric values of western blot analysis showing the effect of
forskolin (adenylyl cyclase stimulator) on the amount of phospho-ERKl/2
protein in NCI-H322 cells (PACC). Cells were plated and maintained in high
serum medium until 70-80% confluency. Medium was then replaced with
low serum medium containing forskolin ( 1 0 µM) and incubated for the
indicated periods. At the end of the respective incubation period, cells were
harvested for western blot analysis. Bars represent the mean ERK/actin pixel
ratio as a percentage of the mean value of the control group (0 hr) that was
normalized at 1 00%. Means in each treatment group were compared with the
mean from the control group using ANOV A with Dunnet comparison.
Forskolin induced significant activation of ERKl/2 as early as 1 5 minutes.
(ns -non significant/p>0.05;

** - p<0.0 1 ; * - p<0.05 ; *** - p<0.00 1 ).
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Figure 29. Western blot of Phospho-MAPK showing the effect of the adenylyl
cyclase stimulator, forskolin on ERK.1/2 activation in NCI-A549 cells (PAC-type
II). Cells were plated and maintained in high serum medium until 70-80%
confluency. Medium was then replaced with low serum medium containing
forskolin ( 1 0 µM) and incubated for the indicated periods. At the end of the
respective incubation period, cells were harvested for western blot analysis.
Forskolin induced early activation of ERK.1/2. This was followed by persistent
inhibition Actin bands serve as an internal control for equal protein loading.
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Figure 30. Densitometric values of western blot analysis showing the effect of
forskolin (adenylyl cyclase stimulator) on the amount of phospho-ERK.1/2
protein in A549 cells (PAC type-II). Cells were plated and maintained in high
serum medium until 70-80% confluency. Medium was then replaced with low
serum medium containing forskolin (10 µM) and incubated for the indicated
periods. At the end of the respective incubation period, cells were harvested for
western blot analysis. Bars represent the mean ERK/actin pixel ratio as a
percentage of the mean value of the control group (0 hr) that was normalized at
100%. Means in each treatment group were compared with the mean from the
control group using ANOVA with Dunnet comparison. Forskolin induced
significant early activation of ERK.1/2. This was followed by persistent and
significant inhibition. (ns -non significant/p>0.05;
p<0.001).
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Figure 31. Immunoprecipitation and western blot of the epidermal growth factor
receptor (EGFR) showing the effect of the adenylyl cyclase stimulator, forskolin (10
µM), on tyrosine-phosphorylation/activation of the EGFR in NCI-A549 cells (PAC
type II). Cells were plated and maintained in high serum medium until 70-80%
confluency. Medium was then replaced with low serum medium containing forskolin
(10 µM) and incubated for the indicated periods. At the end of the respective
incubation period, cells were harvested for analysis. Tyrosine phosphorylation of the
EGFR was detected with an antiphosphotyrosine monoclonal antibody. Forskolin did
not inhibit EGFR tyrosine phosphorylation except at 24 hour. The EGFR bands serve
as an internal control. No significant difference observed in the total EGFR in the
immunoprecipi tation product.

79

A549
0::

LL

w

"C -

200......----------------------,
1 80 ----- ---------------------------------------------------------------------------------------------------------1 6 0 ---------- - ---------------------------------------------------------------·---- - -----------------------------------

*

140 ___________________________________________________________________ ns ---------- - - ------------ --------------------

.! ';le 1 20 -

ca -

ns

-----·------ --- --- - f ""--""'t---

1 00 -
'5'a3
... >

_g �
C.
U)

0
.c:
0..

--

80

60 -- -

40 - - -------------- ----- ---------- ---

c::J Control
- Forskolin
(10 µM)

20 --- ----------- ----- ----------- ---

0 ...___.____._____.___.....___
3 0 min 30 min
0

8hr

8hr

24hr

24hr

Time

Figure 32. Densitometric values of immunoprecipitaion and western blot
analysis showing the effect of forskolin (adenylyl cyclase stimulator) on tyrosine
phosphorylation of the EGFR in A549 cells (PAC type-II). Cells were plated and
maintained in high serum medium until 70-80% confluency. Medium was then
replaced with low serum medium containing forskolin ( 1 0 µM) and incubated
for the indicated periods. At the end of the respective incubation period, cells
were harvested for analysis. Bars represent the mean phospho-EGFR/total EGFR
pixel ratios as percentage of the mean value of the control group at 0-hr that was
normalized at 1 00%. Means in each treatment group were compared with the
mean from the respective control group with paired t-test. Values with asterisks
significantly differ from each other and the 0-hr control in the amount of tyrosine
phosphorylated EGFR. (ns -non significant/p>0.05 ;
- p<0.00 1 ).
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Figure 33. Effect of propanolol (broad-spectrum �-adrenergic antagonist) and
SQ22536 (adenylyl cyclase inhibitor) on isoproterenol- and forskolin-induced
DNA synthesis in NCI-H322 cells (PACC). Cells were plated and incubated in
high serum medium for 24 hours. Medium was replaced to low serum condition to
starve cells for 24 hours. After the starvation period, fresh low serum medium
containing antagonists was added and incubated for 20 minutes. This was followed
by the addition of agonists and incubation for 24 hours. All wells contained 0.5 µCi
of [ 3 H]-thymidine. Low serum medium and DMSO were used as controls for
isoproterenol and forskolin, respectively. Bars represent the mean CPM ± SE of
each treatment group from three independent experiments as percentage of mean
value of the control groups normalized as 100%. Means in each treatment group
were compared with the mean from the respective control groups using ANOVA
with Dunnet comparison. SQ22536 nullified isoproterenol- and forskolin-induced
DNA synthesis. Similarly, isoproterenol-induced DNA synthesis was blocked by
propanolol. The vehicle (DMSO) had no significant effect on DNA synthesis. (ns non significant/p>0.05;

** - p<0.0 1 ; * - p<0.05; *** - p<0.00 1)
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Figure 34. Effect of SQ22536 (adenylyl cyclase inhibitor) on forskolin-induced
inhibition of DNA synthesis in A549 cells (PAC-type II). Cells were plated
and incubated in high serum medium for 24 hours. Medium was replaced to
low serum condition to starve cells for 24 hours. After the starvation period,
fresh low serum medium containing SQ22536 was added and incubated for 20
minutes. This was followed by the addition of forskolin and incubation for 24
hours. All wells contained 0.5 µCi of [3H]-thymidine. DMSO was used as a
vehicle/control for forskolin. Bars represent the mean CPM ± SE of each
treatment group from three independent experiments as percentage of mean
value of the control groups normalized as 1 00%. Means in each treatment
group were compared with the mean from the respective control groups using
ANOVA with Dunnet comparison. SQ22536 nullified forskolin-induced
inhibition of DNA synthesis. (ns - non significant/p>0.05 ;
p<0.05 ;

* * * - p<0.00 1 )
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Figure 3 5 . Effect of the EGFR-specific tyrosine kinase inhibitor, AG1478, on
isoproterenol- and forskolin-induced DNA synthesis in NCI-H322 cells (PACC). Cells
were plated and incubated in high serum medium for 24 hours. Medium was replaced
to low serum condition to starve cells for 24 hours. After the starvation period, fresh
low serum medium containing AG 14 78 was added and incubated for 20 minutes. This
was followed by the addition of isoproterenol or forskolin and incubation for 24 hours.
All wells contained 0.5 µCi of [3 H]-thymidine. Low serum medium and DMSO were
used as vehicle/controls for isoproterenol and forskolin/AG 1478, respectively. Bars
represent the mean CPM ± SE of each treatment group from three independent
experiments as percentage of mean value of the control groups normalized as 100%.
Means in each treatment group were compared with the mean from the respective
control groups using ANOVA with Dunnet comparison. AG1478 (lµM) blocked
isoproterenol- but not forskolin-induced DNA synthesis. At 10 µM, AG1478 blocked
both isoproterenol/ forskolin-induced and basal DNA synthesis. The vehicle (DMSO)
had no significant effect on DNA synthesis (ns - non significant/p>0.05 ;

* - p<0.05 ; *** - p<0.001)
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Figure 36. Effect of propanolol (broad-spectrum P-adrenergic antagonist), ICI118551 (B2 adrenergic antagonist), atenolol (B l adrenergic antagonist), the SQ22536
(adenylyl cyclase inhibitor) on isoproterenol-induced DNA synthesis in NCI-H322
cells (P ACC). Cells were plated and incubated in high serum medium for 24 hours.
Medium was replaced to low serum condition to starve cells for 24 hours. After the
starvation period, fresh low serum medium containing the various antagonists was
added and incubated for 20 minutes. This was followed by the addition of
isoproterenol and incubation for 24 hours. All wells contained 0.5 µCi of [3 H]
thymidine. DMSO was used as a vehicle for SQ22536. For the rest, low serum
medium was used as a vehicle/controls. Bars represent the mean CPM ± SE of each
treatment group from three independent experiments as percentage of mean value of
the control groups normalized as 100%. Means from each treatment group were
compared with the mean from isoproterenol group using ANOVA with Dunnet
comparison. All antagonists, showed significant inhibition of isoproterenol-induced
DNA synthesis. (ns -non significant/p>0.05;

84

** - p<0.01; * - p<0.05; *** - p<0.001)

Basal and isoproterenol/forskolin-induced cAMP level

The basal and isoproterenol- or forskolin-mediated cAMP concentration was assayed
with competitive ELISA. Cyclic AMP concentrations were expressed as pM/mg of
protein.

The basal cAMP concentration in NCI-H322 cells was significantly higher (3.8 fold) than
that of A549 cells (p<0.00 1) (Figure 37).

Isoproterenol (1 µM) significantly increased intracellular cAMP concentration in NCI
H322 cells (p<0.001) (Figure 38). This represented a nearly 700% increase as compared
to untreated controls. On the other hand, Isoproterenol had no si gnificant effect on
intracellular cAMP concentration in A549 cells (p>0.05) (Figure 39).

The isoproterenol-induced cAMP accumulation was si gnificantly reduced by ICI-118551
(selective P2-adrenergic antagonist) or atenolol (selective

p1-adrenergic

antagonist)

(P<0.001). A more marked reduction (70%) was observed with atenolol than with ICI118551 (50%) (P<0.05) (Figure 40)

Forskolin, at both 1 µM and 10 µM, induced a significant and marked increase in the
intracellular cAMP concentration in NCI-H322 cells (p<0.001) (Fig 38). There was an
approximate 860% and 1100% increase for 1 µM and 10 µM, forskolin, respectively.
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On the other hand, a significant, but less marked increase in intracellular cAMP levels
was induced in A549 cells by forskolin (1 µM and 1 0 µM, p<0.05) (Figure 39). There
was approximate 32% and 44% increase for 1 µM and 1 0 µM, forskolin, respectively. In
contrast to NCI-H322 cells, there was no significant difference between 1 µM and 1 0 µM
forskolin treatments in the concentration of cAMP (p>0.05).
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Figure 3 7. Relative basal cAMP concentration in the human pulmonary
adenocarcinoma cell lines, A549 (PAC-type II) and NCI-H322 (PACC). Cells
were pre-incubated with l mM 3-isobutyl 1 -methylxanthine (phosphodiesterase
inhibitor) for 30 minutes before measurement of cAMP. Bars represent the
cAMP concentration (mean± SE) as percentage of the mean concentration in
the A549 cells normalized at 1 00%. Mean cAMP concentration was compared
with unpaired t-test. Mean. The basal cAMP concentration in NCI-H322 cells
was significantly higher. (ns-non-significant/p>0.05 ;

*** - p<0.00 1 ).
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Figure 38. Effect of isoproterenol (broad spectrum �-adrenergic agonist)
and forskolin (adenyly cyclase stimulator) on cAMP accumulation in the
human pulmonary adenocarcinoma cell NCI-H322 cells (PACC). Cells
were

pre-incubated

with

l mM

3-isobutyl

1 -methylxanthine

(phosphodiesterase inhibitor) for 30 minutes. Fresh low serum medium
containing the indicated agents were added and incubated for 20 minutes.
Bars represent the cAMP concentration (mean± SE) as percentage of the
mean value in the control group that was normalized at 1 00%. Means in
each treatment group were compared with the mean from the control group
using ANOVA with Dunnet comparison. Both isoproterenol and forskolin
induced significant cAMP accumulation. (ns- non significant/p>0.05;
p<0.01 ;

* - p<0.05 ; *** - p<0.00 1 ).
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Figure 39. Effect of isoproterenol (broad spectrum � -adrenergic agonist) and
forskolin (adenyly cyclase stimulator) on cAMP accumulation in the human
pulmonary adenocarcinoma cell A549 (PAC type-II) . Cells were pre-incubated
with lmM 3-isobutyl 1-methylxanthine (phosphodiesterase inhibitor) for 30
minutes. Fresh low serum medium containing the indicated agents were added
and incubated for 20 minutes. Bars represent the cAMP concentration (mean±
SE) as percentage of the mean value in the control group group normalized at
100%. Means in each treatment group were compared with the mean from the
control group using ANOVA with Dunnet comparison Forskolin induced
significant cAMP accumulation. (ns- non significant/p>0.05 ;
p<0.05 ;

*** - p<0.00 1).
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Figure 40. Effect of atenolol (selective � 1 -adrenergic antagonist) and ICI1 1 855 1 (selective �2-adrenergic antagonist) on isoproterenol-induced cAMP
accumulation in NCI-H322 cells (PACC). Cells were pre-incubated with 3isobutyl 1 -methylxanthine, phosphodiesterase inhibitor, for 30 minutes. Cells
were then incubated with antagonists for 20 minutes. This was followed by
addition of isoproterenol and incubation for 20 minutes. Bars represent the
cAMP concentration (mean± SE) as percentage of the mean concentration in
isoproterenol treatment group that was normalized at 1 00%. Means in each
treatment group were compared with the mean from the isoproterenol group
using ANOVA with Dunnet comparison. Both atenolol and ICI- 1 1 85 5 1
significantly inhibited isoproterenol-induced cAMP accumulation. (ns- non
significant/p>0.05 ; ** - p<0.0 1 ; * - p<0.05 ; *** - p<0.00 1).
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IV.

DISCUSSSION

The Epidermal growth factor receptor and cell proliferation

Effect of serum on proliferation

In both cell lines, significantly higher DNA synthesis was observed in low-serum
condition. This is in contrast with most reports where serum stimulates DNA synthesis
and proliferation (Bihl et al., 1998; Thrane and Schwarze, 2001). Comparable findings to
ours have been reported recently by Murphy et al. (2001b), who showed increased DNA
synthesis and proliferation in pancreatic adenocarcinoma cells weaned from high-serum.
In a related study, Murphy et al. (2001a) showed that pancreatic adenocarcinoma cells
proliferate indefinitely in serum-free medium by overexpression of the epidermal growth
factor receptor and overproduction of TGF-a. Bost et al. (1997) reported a doubling time
of 60 hours in low-serum medium for A549 cells. Serum-free medium conditioned for 72
hours by A549 cells stimulate colony formation of normal bronchial epithelial cells, and
A549 cells themselves suggesting the presence of released autocrine growth factors
(Siegfried, 1987). Proliferation of monolayer cells is significantly reduced by contact
inhibition at full confluence. It could then be reasoned that cells in high-serum medium
had reached near/at confluence and would transition to a state of reduced DNA synthesis.
However, in this study confluence at the end of incubation and DNA harvest varied
between 60-70% ruling out contact inhibition as a possible cause of lower DNA synthesis
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in high-serum. Croce et al. (1 999) showed the lack of anchorage dependency in parental
A549 cells. These investigators described that three of the four subpopulations of A549
cells grow as a well-spread monolayer while one of them tends to form cell aggregates
that pile up on the monolayer. Consequently, cells assume pavement-like structures as
culture approach confluence and start to pile up as a result of anchorage independency
(Croce et al., 1 999). This growth characteristic was also observed in the A549 cells in the
present study. Therefore, contact inhibition might not dramatically prevent these cells
from proliferation as observed in our study. However, as stated earlier, the low
confluency level at the time of cell harvest rules out this possibility as the source of such
a marked variation.
We also found that replacement of the medium with fresh low-serum medium every 1 2
hours led to a significant inhibition o f DNA synthesis i n both cell lines. B y contrast,
DNA synthesis in the second control group where the primed medium was temporarily
removed, saved, and replaced showed no significant difference compared to that of the
continuous-culture control. The comparable DNA synthesis in the two control groups
rules out the physical interference from the repeated medium removal and replacement as
a significant factor for the difference in DNA synthesis. Together, these observations
point to the presence of secreted endogenous growth stimulatory factors in the culture
medium. An internal constitutive autocrine loop without the need for growth factors in v
sis transformed cells has been reported in various cells (Keating 1 988; Bejcek et al.,
1 989). Our observation suggests a less significant role of for an internal growth loop
because removal of the conditioned medium caused a marked reduction in DNA
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synthesis implying dependence on released growth factors. However, medium removal
might remove other extracellular components besides growth factors that might be
needed for optimal cell growth and survival. Therefore, our findings do not completely
rule out this possibility although they strongly suggest the presence of autocrine growth
factors.
In both cell lines, the higher DNA synthesis in low-serum condition was evident as early
as the fourth hour of incubation, which implies DNA synthesis was stimulated by low
serum even earlier. In support this interpretation, an early (30 minutes) ERK.1/2
activation was observed in A549 cells following medium change from high to low-serum.
This activation was maintained throughout the 24-hour incubation in low-serum medium
consistent with the higher and significant DNA synthesis observed at all sampling points
compared to the high-serum environment. Early response genes such as c-fos and c-jun
are induced within minutes of the addition of growth factors to quiescent cells (Lodish et
al., 2000). The early activation of MAPK/ERK after medium change is not surprising
because these early response genes are induced by MAPK. Murphy et al. (200 1b)
reported MAPK/ERK, c-jun, and c-fos mRNA content was significantly elevated in
pancreatic cancer cells cultured continuously in serum free medium. This activation
might suggest a disinhibitory role of low-serum. Serum contains several defined and
undefined factors that stimulate or inhibit the growth of cultured cells. Growth inhibitory
factors in serum such as TGF-P antagonize EGF- induced colony formation (Tada et al.,
2000) and mediate growth arrest (Bennett, 1999) in A549 cells. TGF-P mediates the shift
of A549 cells back to a normal senescence via inhibition of tel omerase activity. However,
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this effect was not accompanied by complete growth arrest (Katakura et al., 1 999). In a
study by Bennett ( 1 999), growth inhibition by TGF-� was accompanied by a reduction of
the expression and secretion of amphiregulin, a member of the EGF/TGF-a family.
Transforming growth factor-beta (TGF-�) or other factors in serum might interfere or
suppress the release of preformed growth factors in a similar manner. Consequently, low
serum might facilitate the release of growth factors for subsequent self -stimulation.
In normal cells, the supply of preformed stored peptide hormones is sufficient for growth
stimulation for about a day (Lodish et al., 2000). We have observed that higher DNA
synthesis

m

low-serum

persisted

up

to

48

hours.

This

might

suggest

overexpression/storage of growth factors, which is a characteristic feature of most solid
tumors. Furthermore, receptors and ligands for autocrine growth pathways are up
regulated when cancer cells are adapted to serum-free culture (Murphy et al., 200 1 a).

Effect ofEGF, TGF-a, and EGF antibody on DNA synthesis

In the present study, both EGF and TGF-a failed to significantly modulate DNA
synthesis in A549. This cell line expresses the EGFR, and its proliferation is mediated by
this receptor (Al Moustafa et al., 2002). The EGF receptor binds various ligands
including EGF, TGF-a, amphiregulin, heparin-binding EGF like growth factor,
betacellulin, and epiregulin (Gschwind et al., 200 1 ). There are varied reports as to the
type of ligands that cause activation of the receptor to induce a proliferative response in
A549 cells (Bost et al., 1 999; Thrane and Schwarze, 200 1 ). Imanishi et al. ( 1 988)
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detected TGF-a receptors in A549 cells along with TGF-a in medium conditioned by
A549 cells. These investigators also stimulated growth of this cell type with exogenous
TGF-a. Antibody against TGF-a but not antibody against EGF resulted in reduced
proliferation in A549 cells indicating TGF-a as an autocrine growth factor in these cells
(Imanishi et al., 1988). Likewise, Thrane and Schwarze (200 1) showed that EGF
treatment does not stimulate DNA synthesis despite transient ERK activation. TGF-a has
been shown to increase the expression of cyclooxygenase-2 (COX-2) in A549 cells, an
enzyme frequently localized at invasive edge of early-stage lung adenocarcinomas (Niki
et al., 2002). On the other hand, EGF was identified as a potent stimulator of cell
proliferation in these cells, and it was shown that the Jun kinase/stress-activated protein
kinase (JNK/SAPK) pathway was an essential mediator of this effect (Bost et al., 1997).
The proliferative effect of EGF in A549 cells has also been shown by (Al Moustafa et al.,
2002). Choudhury et al. (2000) and Croxtall et al. (2000) showed that EGF-activated
ERK caused phosphorylation and activation of cytosolic phospholipase A2 (PLA2)
leading to the release of arachidonic acid (AA) and cell proliferation in A549 cells. Bost
et al. ( 1997) showed a proliferative effect of EGF by continuous daily addition of 10 nm
rhEGF. Continuous EGF treatment induced no significant effect on DNA synthesis in this
study. EGF must continuously interact with receptors for many hours before cells enter
into the DNA synthesis phase (S-phase) of the cell cycle (Boulougouris and Elder, 200 1 ).
Moreover, quiescent cells need 14- 16 hours to pass the restriction point and enter the
DNA synthesis phase (S-phase) of the cell cycle, which lasts for 6-8 hours (Lodish et al.,
2000). It is, therefore, reasonable to assume that the 24-hour incubation time was long
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enough to allow cells to advance well into the DNA synthesis in EGF containing medium
in our studies. Therefore, our finding suggested that EGF is not a potent/primary EGFR
ligand.
Although we did not observe stimulation of DNA synthesis in A549 cells even with high
EGF concentration (200 ng/ml), an antibody against EGF caused significant, though
minor, inhibition. A possible explanation for this effect is that this cell line might produce
enough EGF to maintain maximal proliferation in low-serum in an autocrine or paracrine
fashion. In support of this explanation, DNA synthesis was significantly higher in low
serum medium, and it was inhibited when the primed medium was replaced periodically.
Therefore, the addition of exogenous EGF might be rendered inconsequential by a
saturated self-stimulatory mechanism whereas antibody against EGF would neutralize
endogenous EGF and inhibit proliferation. A dual effect of EGF on tumor cell lines that
overexpress the EGFR has been documented where low concentration (pM levels)
stimulated growth whereas higher concentrations (nM levels) inhibited growth and
facilitated differentiation (Boulougouris and Elder, 200 1 ). These investigators proposed
that in such cells, low doses of EGF may cause only transient stimulation of the MAPK
pathway, resulting in proliferation, whereas higher doses cause sustained stimulation of
the MAPK pathway, leading to differentiation. EGF and TGF-a cause motility,
expression of cell adhesion molecules, and the appearance of fibroblastic morphology in
several epithelial cells (Chen et al., 1 993). Similarly, EGF and heparin-binding EGF like
growth factor induced epithelial-like to fibroblastic conversion and stimulated motility in
NCI-H322 and A549 cells (Al Moustafa et al., 2002). Treatment with antibody against
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the EGFR induced upregulation of E-cadherin and suppression of motility (Al Moustafa
et al., 2002). In related studies, EGFR overexpression has been associated with
invasiveness and metastasis in A549 cells (Niki et al., 2002) and other cancer types
(Fontanini et al., 1 995; Nguyen et al., 2000). These investigations are in accord with our
observation that EGF induced fibroblastic appearance in A549 cells at high
concentrations. Treatment with EGF induced characteristic spindle or multi-appendage
morphological transformation. Up regulation of matrix-degrading proteases such as
matrix metalloproteases (MMPs) via EGFR-mediated signaling has been proposed to
explain this phenomenon (Boulougouris and Elder, 200 1 ; Nguyen et al., 2000). In
addition, invasive tumor cells exhibit dysregulated motility in response to growth factors.
Consequently, growth factor receptor-mediated motility has been suggested as one of the
most common aberrations in tumor cells leading to invasiveness. In this regard, the EGF
and hepatocyte growth factor (HGF) is particularly associated with tumor invasion
(Wells, 2000). Niki et al. (2002) reported that the EGFR might be involved in the
invasive mechanisms of A549 cells. In summary, our data suggests that EGF mediates
non-proliferative morphological effects in A549 cells, which might play a role in
metastasis and invasion.
Earlier reports suggest EGF might not be the primary growth factor in this cell line
(lmanishi et al., 1 988; Thrane and Schwarze, 200 1 ), A549 cells express amphiregulin
(Bennett, 1 999) and heparin binding EGF (Al Moustafa et al., 2002), which are potent
ligands for the EGFR. Therefore, the minor but significant inhibitory effect of EGF
neutralization might suggest a secondary role of EGF in the proliferation of A549 cells.
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On the other hand, the presence of an internal constitutively activated receptor might also
nullify the effect of exogenous growth factors. However, as reasoned earlier, the highly
significant reduction of DNA synthesis in interrupted culture, strongly suggests
dependency

on

released/externally

acting

growth

factors

instead

of

an

internally/constitutively-activated receptor.
The EGFR (ERB l ) and ERB2 are highly expressed in NCI-H322 cells (Nguyen et al.,
2000; Al Moustafa et al. , 2002). Moreover, Al Moustafa et al. ( 1 999) demonstrated the
presence of a functional EGFR growth pathway that was inhibited by an antibody against
EGFR. This growth inhibition was paralleled by differentiation from epithelial-like to
epithelial phenotype. Unlike A549 cells, treatment with EGF at a concentration of 2'.: 20
ng/ml stimulated DNA synthesis of NCI-322 cells in this study. In agreement with these
findings, Al Moustafa et al. (2002) also determined that NCI-H322 cells have a
significantly higher proliferative response than A549 cells in the presence of EGF. These
data are also in agreement with Schuller et al. (1 994), who showed the stimulatory effect
of EGF in NCI-H322 cells. In this study, TGF-a did not stimulate DNA synthesis in the
NCI-H322 cells. TGF-a might not be the primary/active EGFR ligand in this cell line.
Nguyen et al. (2000) showed increased secretion of matrix metalloproteases-9 (MMP-9)
with EGF and heregulin-a treatment in NCI-H322 cells. Hepatocyte growth factor (HGF)
induced EGFR phosphorylation, DNA synthesis, and proliferation in NCI-H44 1 , a related
Clara cell line (Chess et al., 1 998). Schuller et al. ( 1 994) showed that exogenous EGF
stimulated NCI-H322 but not H44 1 cells. Therefore, variation in the type of
primary/active ligand for EGFR also exists within similar phenotypes of pulmonary
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adenocarcinoma. On the other hand, EGF-induced morphological change was not
remarkable in NCI-H322 cells as was seen in A549 cells. The epidermal growth factor
may have a differential effect on these two cell lines, where it stimulated cell
proliferation

m

NCI-H322

cells,

while

inducing

a

non-proliferative

morphogenic/metastatic changes in A549 cells.
Genetic instability, which is reflected in tumor heterogeneity, might explain some of our
results that are not in agreement with some of the earlier literature. Genetic instability, a
critical factor in tumor progression, is the hallmark of virtually all-solid tumors (J allepalli
and Lengauer, 2001). Heterogeneity is observed in individual tumors and among tumors
of the same type. Such heterogeneity is the basis for histological, karyotypic, molecular,
physiological, and biochemical differences that are observed in different parts of the
same tumor (Cahill et al., 1999). For instance, heterogeneity in the A549 cell line with
subpopulations of varying morphology, growth behavior, and antigenicity has been
documented (Croce et al., 1999). Depending on the characteristics of the dominant
subpopulation/s, a given tumor cell line might exhibit its own distinct growth and
biochemical characteristics.

Effect ofEGFR-specific tyrosine kinase inhibition on DNA synthesis

In both cell lines, the EGFR specific tyrosine kinase inhibitor AG1478 caused significant
reduction of low-serum-enhanced DNA synthesis. This growth inhibition was
accompanied by marked MAPK inhibition in a time-dependent manner. These findings
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show that these cells are dependent on the EGFR-MAPK mediated self -stimulated
growth in low-serum.
Together with the low-serum proliferation, the observed effect of AG 1 478 points to the
role of a self-stimulated EGFR-mediated proliferative pathway in both cell lines. A
greater proportion of pulmonary adenocarcinomas expresses and overexpresses EGFR
(Rusch et al., 1 993 ; Nakagawa 2001). As will be discussed in the next sections, AG1 478
completely blocked isoproterenol-mediated proliferation in NCI-H322 cells, suggesting
that the EGFR is an essential mediator of the �-adrenergic receptor-mediated growth
signaling pathway. Various EGFR-targeted therapeutic approaches have been developed
to treat various types of cancer types that overexpress the EGFR and its ligands.
Synthetic EGFR tyrosine kinase inhibitors including the synthetic anilinoquinazoline
Iressa/2D1 839 are showing promising results in early clinical trials (Arteaga et al., 2002;
de Bono and Rowinsky, 2002). Iressa considerably enhance the efficacy of cytotoxic
agents against A549 cells (Sirotnak et al., 2000). Similarly, monoclonal antibodies
against the EGFR have been developed with encouraging antitumor activity in early
clinical development (Baselga, 200 1 ; Slichenmyer and Fry 200 1 ).

Effect ofPD98059 (MEKI inhibitior) on DNA synthesis

The mitogen activated protein kinase (MAPK) induces a wide array of responses,
including cell division and differentiation (Seger and Krebs, 1 995). This central signaling
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molecule is necessary and sufficient for cell differentiation or proliferation depending on
the cellular context (vanBiesen et al., 1996; Cowley et al., 1994). Therefore, inhibition of
MEKl (MAPK activator) by PD98059 was employed in this study to assess the role of
MAPK in proliferation/DNA synthesis in the two cell lines. In both cell lines, PD98059
significantly inhibited DNA synthesis, demonstrating the importance of MAPK/ERK in
the proliferation of these cell lines. On the other hand, as will be described in the coming
sections, tyrosine kinase inhibition of EGFR with AG1478 markedly inhibited the
activation of MAPK/ERK. Mitogen activated protein kinase (MAPK) was upregulated
when cells were grown in low-serum condition. These findings strongly suggest that the
EGFR-MEK-ERK pathway is involved in the proliferative signaling of both cell types.
Our finding is in agreement with earlier reports where PD98059 inhibited EGF-induced
and basal ERK activation (Chen et al., 2000; Thrane and Schwarze 200 1 ; Bost et al.,
1 997) and EGF-induced cell migration (Hauck et al. 2001 ). Activated ERK
phosphorylates cytosolic phospholypase-A (2), promoting its translocation to the
membrane where it facilitates the release of AA (Croxtall et al., 2000). MEKI inhibition
by PD98059 abrogates both IL-1 beta and EGF-stimulated arachidonic acid (AA) and
prostaglandin E (PGE) release and cell proliferation in A549 cells (Choudhury et al.,
2000). Arachidonic acid metabolites enhance cell proliferation in various cancer cell
types including pulmonary adenocarcinoma of both phenotypes (Choudhury et al., 2000;
Schuller et al., 1 999).
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The beta-adrenergic/cAMP pathway and cell proliferation

Intracellular cAMP concentration

Data from the cAMP immunoassay showed a significant difference in the basal cAMP
concentration in the two cell lines. The basal level of cAMP in NCI-H322 cells was
nearly 3 .8 times higher than in A549 cells. These data also showed that the intracellular
cAMP concentration in A549 cells was not affected by stimulation of the B-adrenergic
receptors with isoproterenol. Direct stimulation of the adenylyl cyclase enzyme with
forskolin only moderately stimulated cAMP production in this cell line. These responses
of A549 cells are in clear contrast with those observed in the NCI-H322 cells, which
demonstrated a highly significant accumulation of cAMP in response to isoproterenol and
forskolin. Forskolin induced a higher amount of cAMP production than that induced with
isoproterenol at equimolar concentrations. This was not surprising since forskolin directly
stimulates the enzyme adenylyl cyclase. Previous work in the NCI-H322 cells found a
similar result where both forskolin and isoproterenol induced high amount of cAMP
production (Park et al., 1 995).

The low concentration of cAMP production in the A549 cells corresponded well with
previous data generated in alveolar type II cells of mouse and human origins. Mouse
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tumorigenic alveolar type II cells have fewer P-adrenergic receptors. Consequently,
isoproterenol induced a diminished cAMP production (Lange-Carter and Malkinson,
1 99 1 ). Other cancer types also show down regulation of these receptors and
unresponsiveness to P-adrenergic receptor stimulation that has been correlated with
disease progression (Kamp et al., 1 997). Droms ( 1 996) showed that neoplastic alveolar
type II cells of mouse origin have a defective Gas with subsequent inability to transmit
signals from activated G-protein coupled receptors to the effector adenylyl cyclase
enzyme. This defect was bypassed by treating cells with forskolin, which led to
comparable camp production with that of the non-tumorigenic counterparts (Droms,
1 996). Our data are in general agreement with these earlier works. Forskolin induced a
significant but a moderate increase in cAMP concentration in A549 cells that was not
achieved by isoproterenol in our studies. However, this stimulation was very low (32%
and 44% increase) as compared to that observed in NCI-H322 cells (860% and 1 1 00%
increase) for 1 and 1 0 µM forskolin, respectively. The difference in cAMP in basal as
well as stimulated c-AMP amount in these two cell lines could result from the differing
quantity of phosphodiesterase (cAMP-degrading enzyme). Dent et al. ( 1 998) showed that
the total phosphodiesterase enzyme in human bronchial epithelial cells is considerably
lower than in A549 cells. This would obviously result in more degradation of cAMP in
A549 cells with consequent low concentration of cAMP. However, this possibility could
be ruled out in this study because phosphodiesterase activity was inhibited with a
phosphodiesterase inhibitor (3-isobutyl 1 -methylxanthine). Another explanation for the
observed difference in the cAMP concentration may be that various isoforms of adenylyl
cyclase enzymes and tissue-specific expression of specific isoforms exist (Daniel et al.,
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1 998). In summary, our data indicate that NCI-H322 cells have a considerably higher
basal and agonist-mediated intracellular cAMP level than A549 cells.

Effect of isoproterenol and forskolin on cell proliferation in A549 cells

Isoproterenol had no significant effect whereas forskolin inhibited DNA synthesis
inA549 cells. The inhibitory effect of forskolin was blocked by pre-incubation with
SQ22536 (the adenylyl cyclase inhibitor). The site-specific 8-Cl-cAMP (the site-specific
cAMP analogue) reproduced the inhibitory effect of forskolin on DNA synthesis.
Analysis of cell viability by trypan blue exclusion assay showed no significant reduction
in viability of forskolin-treated A549, ruling out cell death as a cause of reduced DNA
synthesis. These data provide evidence that the inhibitory effect of forskolin on
proliferation is mediated by cAMP-dependent pathway. The adenylyl cyclase inhibitor,
SQ22536, did not completely block the forskolin-induced inhibition of DNA synthesis.
Consequently, the trypan exclusion assay was relevant to rule out cytotoxicity as a cause
of inhibition of DNA synthesis. The difference might be explained by the
pharmacodynamic chracterstics of forskolin and SQ22536 vis-a-vis their common target,
the adenylyl cyclase, of which little is known.
The growth inhibitory effect of agents that elevate intracellular cAMP has been
documented in various cell types including lung cancer cells. Cyclic AMP induces the
expression of signaling molecules that inhibit cell cycle progression (Kato et al., 1 994 ).
Site-specific agonists, such as 8-chloro-cAMP are cell cycle specific apoptotic agents in
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neuroblastoma cells (Kim et al., 200 1 c). A related cAMP analogue, 8-bromo-cAMP
suppresses the growth of ovarian cancer cells (Shaw et al., 200 1 ). Yan et al. (2000)
showed that the cAMP/PKA pathway is involved in isoproterenol-induced cell arrest and
apoptosis in lymphoma cells. The cAMP-mediated growth inhibitory mechanism is also
found in human lung carcinoma (Ally et al., 1 989) and in normal and neoplastic alveolar
type II cells of human or mouse origin (Banoub et al. , 1 996).
Beta-adrenergic stimulation is inhibitory to the proliferation of various cancer cell lines.
In this regard, norepinephrine, a physiologic agonist for P-adrenergic receptors, induces
apoptosis in A549 cells and rat alveolar epithelial cells (Dincer et al., 200 1 ). This effect
of norepinephrine was mediated through a- and P-adrenoceptor activation and was
inhibited by propranolol, a broad-spectrum P-adrenergic antagonist (Dincer et al., 200 1 ).
Cyclic AMP/PK.A mediated growth inhibition by isoproterenol also exists in lymphoma
cells (Yan et al., 2000). This is in contrast with our finding that isoproterenol had no
si gnificant effect on the proliferation of A549 cells. As described earlier, isoproterenol
failed to stimulate cAMP production in this cell line.
Up-regulation of P-adrenergic receptors in A549 cells has been associated with growth
inhibition and differentiation (Nakane et al., 1 990). Consequently, the lack of response to
isoproterenol with respect to cAMP production or DNA synthesis could be attributed to
down-regulated receptors. As discussed earlier, related tumorigenic alveolar type II cells
of mouse origin have defects in the beta-adrenergic/cAMP si gnaling pathway {Lange
Carter et al. , 1 992; Droms, 1 996). In support of this explanation, forskolin induced
si gnificant inhibition of proliferation in A549 cells that was paralleled by significant
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increase in the concentration of cAMP. In this study, it was not possible to offset possible
insensitivity by the use of isoproterenol at higher concentrations because of cytotoxicity.
Reduced number of beta-adrenergic receptors and diminished cAMP production upon

P

adrenergic stimulation has been correlated with cancer progression in human chronic
lymphocytic leukemia (Kamp et al., 1 997).

Effect ofIsoproterenol and Forskolin on cell proliferation in NCI-H322 cells

In contrast to our observations in A549 cells, isoproterenol and forskolin significantly
stimulated DNA synthesis in NCI-H322 cells. The stimulatory effect of isoproterenol was
significantly inhibited by preincubation with propanolol (broad-spectrum P-adrenergic
antagonist) and SQ22536 (adenylyl cyclase inhibitor). Similarly, the effect of forskolin
was countered by preincubation with SQ22536. These data clearly show that the
proliferative effect of isoproterenol involves cAMP down stream of P-adrenergic
receptors. These findings are in accord with our earlier observation that Clara cells (NCI
H322 and NCI-H44 1 ) are under the P-adrenergic control (Park et al., 1 995). In both cell
lines, P-adrenergic agonists, including isoproterenol, induced DNA synthesis in a cAMP
dependent fashion (Park et al., 1 995). The effect of isoproterenol was concentration
independent probably suggesting functional P-aderenergic receptors in these cells are
saturated in the lower concentration range as well.
This study shows that preincubation with 1 uM of AG1 478 (the EGFR-specific tyrosine
kinase inhibitor) significantly inhibited isoproterenol but not forskolin-induced DNA
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synthesis in NCI-H322 cells. These data show that isoproterenol-induced DNA synthesis
involves activation of cAMP as well as transactivation of the EGFR pathway. Beta
adrenergic stimulation activates MAPK through EGFR-dependent (Daub et al., 1 996;
Maudsley et al., 2000) or EGFR-independent mechanisms (Schmitt and Stork 2000;
Hoare et al., 1 999). G protein coupled receptor-dependent activation MAPK is cell type
specific and follows different mechanisms mediated by different Gs proteins. Some of
these mechanisms include GuslcAMP-mediated PKA activation and subsequent
activation of B-Raf-MAPK in human embryonic kidney cell (Schmitt and Stork, 2000);
Guq -mediated activation of protein Kinase C (PKC) that activates Raf-MAPK in Chinese
hamster ovary cells (Hoare et al., 1 999); and Gpy;Src-mediated transactivation of receptor
tyrosine kinases with subsequent Ras/MAPK activation in rat fibroblast cells (Daub et al.,
1 996; Maudsley et al., 2000). Maudsley et al. (2000) reported a novel pathway, in which
isoproterenol transactivated EGFR via formation of a heterodimeric complex containing
the B2 adrenergic receptors and the EGFR. Daub et al. ( 1 997) showed that AG 1 478
blocked GPCR stimulated EGF receptor phosphorylation and ERK activation in rat
fibroblast cells. In a similar fashion, Vancorven et al. ( 1 993) showed that the GPCR
ligand thrombin-mediated Ras activation in fibroblasts is abrogated by treatment with
genistein, a tyrosine kinase inhibitor. In addition, AG 1478 (EGFR-specific tyrosine
kinase inhibitor) inhibits alpha-adrenergic receptor-mediated MAKP activation,
demonstrating the role of transactivation mechanism in wider range of adrenergic
receptors (Daniel et al., 1 998). Crespo et al. (1 995) showed that isoproterenol-induced
MAPK activation was inhibited by expression of Ras inhibiting molecules in rat
fibroblast cells.
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In summary, isoproterenol and other GPCR ligand-induced DNA synthesis is mediated
through the transactivation of the various receptor tyrosine kinases in many types of cells.
As discussed earlier, a higher concentration ( 1 0 µM) of AG1 478 inhibited both
isoproterenol-induced and basal DNA synthesis. These findings suggest that, in the NCI
H322 cells, the EGFR pathway is not only activated by agonists of the EGFR but also by
binding of agonists to the beta-adrenergic receptors.
The NCI-H322 cells were stimulated also by forskolin, an effect that was significantly
countered by preincubation with the adenylyl cyclase inhibitor, SQ22536. These findings
imply that a cAMP-dependent proliferative pathway is present in NCI-H322 cells in
addition to the GPCR-RTK transactivation pathway. This implies also that in contrast to
A549 cells, cAMP-dependent PKA may have a stimulatory instead of inhibitory role in
NCI-H322 cells. Cyclic AMP and agents like forskolin that cause cAMP accumulation
prevent apoptosis induced by DNA topoisomerase II inhibitors in promonocytic leukemia
cells (Garcia-Bermejo et al., 1 998). Lazou et al. ( 1 994) showed that isoproterenol and
norepinephrine stimulated MAPK activation in isolated rat heart. Cyclic AMP-induced
MAPK activation has also been reported by Faure et al. (1 994), who showed the presence
of regulatory differences between cells indicating that G proteins and second messengers
regulate MAPK pathway and growth in a cell-type specific manner. A novel signaling
pathways where cAMP activates selected Raf isotypes, hence MAPK, in a PKA
dependent and independent manner have been shown by Vossler et al. ( 1 997) and
Schmitt and Stork (2000). The type and expression of the Raf isotypes might decide the
effect of intracellular accumulation of cAMP (Gao et al., 1 999; Seidel et al., 1 999).
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Therefore, the stimulatory effect forskolin in NCI-H322 cells might be explained by the
type and amount of expression of Raf. Therefore, cAMP/PKA could activate or inhibit
the MAPK pathway in a cell type-specific manner (Graves and Lawrence, 1996; Schmitt
and Stork 2000).

Effect offorskolin on MAPK activation in A549 cells

The role of cAMP as a counter regulator of signals generated by growth factors has been
described in various cell lines (Graves and Lawrence, 1996; McCawley et al., 2000). In
this study, forskolin inhibited the low-serum-induced DNA synthesis and MAPK
(ERK1/ERK2) activation of A549 cells.
This study showed that forskolin caused an early stimulation of MAPK followed by a
consistent inhibition in A549 cells. This is in agreement with the thymidine incorporation
data of this study, where forskolin induced significant inhibition of DNA synthesis in this
cell type. Similar findings were reported by Lieberman et al. (1996a), who showed that
forskolin inhibited EGF-induced MAPK activation and cellular proliferation in pancreatic
adenocarcinomas. The inhibitory effect of cAMP on MAPK activation may occur at
various levels of the EGFR-MAPK pathway. Inhibition of Raf-1 by cAMP dependent
PKA has been well documented (Seger and Krebs, 1995; Piiper et al., 2000). Enhanced
expression of the regulatory (RI alpha) subunit of cyclic AMP-dependent protein kinase
(PKA) has been correlated with cancer cell growth. Moreover, this PKA inhibitory
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protein is overexpressed in various cancer cell lines and tumor tissues including human
ovarian cancer (McDaid et al., 1 999) and Lewis lung carcinoma of mouse origin (Young
et al., 1 995). Consequently, inhibition/depletion of this regulatory protein by antisense
oligoneucleotides suppresses the growth of human breast, colon, and gastric cancer
(Yokozaki et al., 1 993) and pulmonary adenocarcinoma of A549 cell origin (Wang et al.,
1 999).
The MAPK pathway is constitutively activated in A549 cells that harbor an activating
Ras mutation that is necessary to maintain cell proliferation in these cells (Hoshino et al.,
1 999). The activation of MEK, which is a critical mediator of this pathway, is inhibited
by pertusis toxin, which increases intracellular cAMP by inhibiting the activity of Gai
protein (Yano et al., 2002). The inhibition of MEK activation was associated with cAMP
mediated stimulation of PKA activity (Yano et al., 2002). The data from this study
together with earlier observations by others, point to the fact that a minor increase in in
the concentration of cAMP is inhibitory to the MAPK proliferative pathway in A549
cells. In the present study, the quantity of the catalytically active form of ERKl/2 was
considerably reduced after 8 hours of incubation in A549 cells treated with forskolin ( 1 0
µM). However, the cAMP assay data showed that the levels o f cAMP were elevated only
by about 40% above the basal level after 20 minutes of incubation with forskolin at a
concentration of 1 0 µM. It is possible that a significantly higher cAMP accumulation
would have been observed with longer incubations similar to those for the MAPK and
thymidine incorporation assay. This could be more pronounced in view of the likely low
amount of cAMP degrading enzyme in A549 cells, which can further contribute to
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enhanced cAMP accumulation (Dent et al., 1998). This suggests a possibility that in
A549 cells the concentration of cAMP is more tightly regulated considering its growth
inhibitory role. A minor increase in the concentration of cAMP would be detrimental to
these cells. In support of this explanation, an approximate 60% increase in cAMP
concentration by pertusis toxin caused a significant reduction in the amount of activated
MEK that was accompanied by a significant PKA stimulation in A549 cells (Yano et al.,
2002). In line with this interpretation, enhancing the activity of the cAMP-dependent
PKA has been proposed as a potential cancer therapeutic approach alone or in
combination with conventional chemotherapy in malignancies involving A549 cells
(Wang et al., 1999).

Effect offorskolin on MAPK activation in NCI-H322 cells

Consistent with its observed mitogenic effect, forskolin ( 10 µM) induced a persistent
MAPK activation in NCI-H322 cells in contrast to its mainly inhibitory effect in A549
cells. The amount of activated MAPK was significantly upregulated as early as 15
minutes post treatment and was maintained throughout the 24-hour period in the NCI
H322 cells. The cAMP concentration following treatment with forskolin ( 10 µM) showed
about an 1 1-fold increase within 15 minutes. This paralleled the early stimulation of
MAPK. There is limited information as to the mechanisms by which cAMP induces
MAPK activation. In a recent report, Hanke et al. (200 1) showed that the cAMP-PKA
pathway is essential for the transactivation of EGFR. These investigators demonstrated
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that specific inhibitors of PKA reduced the EGFR transactivation in response to
isoproterenol. The mechanism of this transactivation includes stimulation of P-adrenergic
receptors which leads to Gas -mediated increase in cAMP concentration, after which
protein

kinase

A (PKA) phosphorylates

P-adrenergic receptors (heterlogous

desensitization), which is followed by switching from Gas to Gai protein. This is followed
by MAPK activation by Gui-derived Py-complexes and Ras (Hanke et al., 200 1 ). This is
in contrast with other reports in other cell lines, where the cAMP-PKA pathway inhibits
EGFR activation (Mitsui and Iwashita, 1 990; Iwashita et al., 1 990; Stadtmauer and
Rosen, 1 986).
Recently, a novel signaling pathway in which cAMP activates MAPK in PKA-dependent
and independent manner has been demonstrated (Vossler et al., 1 997; Schmitt and Stork
2000). Protein kinase A (PKA) activates Rap l , which in tum activates B-Raf. On the
other hand, cAMP can directly activates the EPAC (cAMP-GEFs/cAMP-Guanylyl
Exchange Factor), which activates B-Raf directly and independent of PKA (de Rooij et
al., 1 998; Kawasaki et al., 1 998). The type of Raf isotypes is an important precondition to
determine inhibition or stimulation of MAPK by cAMP (Gao et al., 1 999; Seidel et al.,
1 999). Consequently, the marked differential effect of forskolin on cell proliferation and
MAPK activation in the A549 and NCI-H322 cell lines might be attributed to a difference
in the type and amount of expression of Raf-B or Raf- 1 . Therefore, cAMP/PKA could
activate or inhibit the MAPK pathway in a cell type-specific manner (Graves and
Lawrence, 1 996; Schmitt and Stork 2000). Contradictory effects of cAMP on mitogenic
signaling might also result from cellular specificities in concentration, types, and
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localization of the cAMP-dependent protein kinases (PK.A) (Lange-Carter and Malkinson
1 99 1 ).
In both cell types, the level of activated MAPK (p-ERK.1 /2) moderately declined after the
initial surge as a result of forskolin treatment. However, contrary to the persistent and
marked inhibition observed in A549 cells, the moderate decline in the level of MAPK in
NCI-H322 cells was reversible with maximal activation at 24 hours treatment. This may
suggest the presence of a mechanism to regulate MAPK activation within a certain
optimal level. Barbier et al. (1999) proposed serine-phosphorylation of the EGFR by the
cAMP/PKA as a regulatory mechanism of the amount of MAPK activation. On the other
hand, PK.A might have a dual effect on the MAPK regulation in that it activates MAPK
upstream via Gai (Hanke et al., 200 1) and inhibits its activation by acting down-stream at
the level of Raf-1 (Seger and Krebs, 1995; Piiper et al., 2000). The balance between the
two pathways might determine the net response to signals mediated through the cAMP
PKA pathway in a cell-type specific manner. This might also attribute to the more or less
cyclic trend of activated MAPK observed in the NCI-H322 cells.

Effect offorskolin on tyrosine phosphorylation of the EGFR

The inhibition of MAPK by forskolin observed in this study could result from the
inhibition of tyrosine phosphorylation of the EGFR by cAMP dependent PK.A (Barbier et
al., 1999; Nair and Patel 1993). Cyclic AMP-dependent inhibition of EGFR activation
may be cell-type dependent. Inhibition of the EGFR and related receptors occurs in
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various cancer cell types (Mitsui and Iwashita, 1 990; Iwashita et al., 1 990; Stadtmauer
and Rosen, 1 986). We wanted to determine if forskolin-mediated MAPK in A549 cells
occurs at the EGFR level. This is particularly important since the EGFR is commonly
expressed in a greater proportion of the NSCLC (Rusch et al., 1 993 ; Nakagawa 2001).
Immunoprecipitation of the EGFR receptor followed by immunoblotting with an
antibody against phosphotyrosine was done after treating cells with forskolin in an
attempt to address this question.
Forskolin did not significantly modulate EGFR phosphorylation/activation at 30-minutes
and 8-hours of incubation. Significant inhibition was observed after 24 hours of
incubation. Highest amount of activated MAPK was observed at 30-minutes wherease
lowest amount was obsereved at 8 and 24 hours of incubation. Significantly reduced
DNA synthesis was found after 24-hour treatment with forskolin. Consequently, these
time intervals were expected to show cAMP-mediated modulation of EGFR tyrosine
phosphorylation, if it existed. However, no such effect was observed after 8 hours, which
had similar degrees of MAPK inhibition as 24 hours. The 24-hour treatment with
forskolin showed significant cell cycle arrest as measured by inhibition of DNA
synthesis. By contrast, a greater proportion of cells in an active cell cycle are expected in
the 24-hour control/untreated group. Hence the 24-hours control group would likely have
greater number of cells with activated/phosphorylated EGFR receptors. Therefore, the
observed down-regulated EGFR phosphorylation after 24-hour incubation in forskolin
could be confounded by a possible lower proportion of newly divided active cells
compared to the control group. In support of this explanation, the amount of
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phosphorylated EGFR in the 24-hour control group was significantly higher than the O hr
control. As reasoned earlier, a comparable down-regulation of EGFR activation at the 8hour time interval was expected since there was a similar down regulation of MAPK as
that of 24-hour forskolin treatment. In summary, our data did not enable us to conclude if
the cAMP-mediated down regulation of ERKl/2 (MAPK) activity observed in A549 cells
acts at the receptor level. Cyclic AMP-dependent inhibition of EGFR activation appears
to be cell type dependent. In some cancer types, growth arrest and MAPK inhibition by
cAMP occurs independent of inhibition of EGFR phosphorylation (Lieberman et al.,
1996b).
In summary, the differential effect of isoproterenol and forskolin in the two cell types
suggests the presence of a cell-type dependent growth-regulatory pathway within
pulmonary adenocarcinomas. The unresponsiveness to the P-adrenergic stimulation in
A549 cells might have arisen from down regulated P-adrenergic receptors, functionally
uncoupled G-stimulatory alpha protein, or functional state of the adenylyl cyclase.
However, the differential response may have been due to cell specific signaling
peculiarities, where cAMP is stimulatory or inhibitory in a cell-type dependent manner.
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V.

CONCLUSION

In the developed world, lung cancer became a major epidemic of the 20th century from a
rare disease at the beginning of the century (Janssen-Heijnen and Coebergh 200 1 ).
Pulmonary adenocarcinoma (PAC), which originates from bronchiolar epitheliaVClara
cells or the alveolar type II cells, constitutes one of the most rapidly increasing lung
cancer types. Depending on the patient population examined, P ACC (Clara cell origin)
and PAC-type II (alveolar type II cell origin) occur in a comparable proportion. Unlike
the non-small cell lung carcinoma, which exists almost exclusively in smokers, PAC
develops in smoking and non-smoking individuals. Consequently, other factors besides
smoking may contribute to the development and progression of PAC.

This study showed that isoproterenol (a broad-spectrum beta-adrenergic agonist) and
forskolin ( a adenylyl cyclase stimulator) induced significant proliferative response in cell
line NCI-H322 (PACC). The selective blocking of the beta 1 and beta 2 adrenergic
receptors and the adenylyl cyclase activity nullified this response, indicating the
involvement of both receptors and cAMP in this proliferative pathway. Furthermore, the
isoproterenol-induced proliferation was abrogated by pretreatment of cells with AG1 478,
an EGFR-specific tyrosine kinase inhibitor. This finding suggested that beta-adrenergic
receptor stimulation transactivates the EGFR pathway. A persistent activation of MAPK
(ERKl /2) accompanied the forskolin-mediated growth stimulation in the NCI-H322 cells.
1 16

Recently, a novel signaling pathway where cAMP activates MAPK in a PK.A-dependent
and independent manner has been proposed (Vossler et al., 1997; Schmitt and Stork,
2000). These studies showed that the involvement of Rap 1-mediated activation of B-raf
is an essential step in this cAMP/PKA-mediated MAPK activation. Consequently, the
type and expression of the Raf isotype may be an important determinant as to whether
cAMP is inhibitory or stimulatory to MAPK activation in a specific cell type (Gao et al.,
1999; Seidel et al., 1999). Consequently, analysis of the dominant Raf isotype and
activity might provide a clue to the contradictory effect forskolin had on cell proliferation
and MAPK activation in the A549 and NCI-H322 cells.

The results from this study are in agreement with previous studies with these and related
cell lines. A potential tumor-promoting mechanism involving the beta-adrenergic/cAMP
signaling pathway has been described in PAC of Clara phenotype (Park et al., 1995 ;
Schuller et al., 1999). The tobacco-specific carcinogen, NNK, is a high affinity beta
adrenergic agonist enhancing this novel growth pathway in PAC (Park et al., 1995 ;
Schuller et al., 1999). According to these studies, beta-adrenergic receptor agonists such
as isoproterenol, epinephrine and agents that cause intracellular accumulation of cAMP
such as theophyilline would promote the development of pulmonary adenocarcinoma. As
a result, the chronic management of respiratory diseases such as asthma, chronic
bronchitis, and chronic obstructive lung disease (COPD) by these agents could pose a
potential risk for the development of PAC (Park et al., 1995 ; Schuller et al., 1999). In
addition, there is considerable epidemiological data showing the association of chronic
respiratory diseases such as bronchitis and COPD and the development of lung cancer
1 17

(Osann, 1 99 1 ; Weiss 1 99 1). A recent study by Brownson and Alavanja (2000) showed a
significant risk of lung cancer in the presence of chronic bronchitis, emphysema, and
pneumonia. Consequently, the possible role of the extensive use of these agents might in
part explain the spatial and temporal co-distribution of chronic respiratory diseases and
lung cancer.

On the other hand, DNA synthesis in A549 cells (PAC-type II) was inhibited by forskolin
and 8-Cl-cAMP. These cells were also unresponsive to beta-adrenergic stimulation with
isoproterenol. No significant effect in DNA synthesis was observed following treatment
with isoproterenol. Cyclic AMP is growth inhibitory in various cell types including lung
cancer. It has been associated with cell cycle arrest and apoptosis in various cancer cell
lines (Kato et al., 1 994; Kim et al., 200 1 c; Yan et al., 2000) including human lung
carcinoma (Ally et al., 1 989). Although limited, data from earlier studies suggested that
the growth of PAC type II of mouse and human origin are inhibited by beta
adrenergic/cAMP pathway (Dincer et al., 200 1 ; Banoub et al., 1 996; Nakane et al., 1 990).
Studies in mouse tumorigenic alveolar type II cells indicated down regulation or
deregulation of the various beta-adrenergic signaling mediators from receptors to the
enzyme effectors (Lange-Carter and Malkinson, 1 99 1 ; Lange-Carter et al., 1 992; Droms,
1 996). Reduced number of beta-adrenergic receptors and diminished cAMP production
upon beta-adrenergic stimulation have also been correlated with progression of chronic
lymphocytic leukemia (Kamp et al., 1 997). Consequently, the lack of responsiveness to
isoproterenol might have arisen from either of the aforementioned defects in the beta
adrenergic/cAMP pathway. In support of this rationalization, data on basal and post1 18

stimulation cAMP concentration showed a marked difference between the two cell lines.
A significantly lower cAMP concentration was found in the A549 cells compared to
NCI-H322 cells. Also, beta-adrenergic stimulation with isoproterenol showed no
significant increase in the concentration of cAMP in A549 cells. This is in complete
contrast with the NCI-H322 cells where isoproterenol induced a marked increase in
cAMP concentration. Contrary to the response to isoproterenol, A549 cells showed a
moderate but significant increase in cAMP concentration following the direct stimulation
of adenylyl cyclase enzyme. However, the increase in forskolin-mediated cAMP amount
was distinctly lower than that observed in NCI-H322 cells. Our data demonstrated a
remarkable difference between the two cell lines. The �-adrenergic signaling pathway
appears to have a dual regulatory function in the normal alveolar type II cells, where it
facilitates a range of physiological processes (Dumasius et al., 2001 ; Isohama et al.,
200 1) while discouraging cell proliferation (Nakane et al., 1 990). Consequently, it might
be reasoned that alveolar type II cells down-regulate the beta-adrenergic/cAMP pathway
during their tumorigenic progression, which would, otherwise, preclude their
uncontrolled proliferation. This transformation to a physiologically incompetent and
proliferative phenotype would be expected to greatly exacerbate the ailing alveolar
physiology. Compromised re-epithelialization of the alveolar surface, which is done by
alveolar type II cells, may result in pulmonary fibrosis (Witschi, 1 990). Consequently, it
could be hypothesized that treatment of chronic respiratory diseases with agents that
stimulate the beta-adrenergic/cAMP pathway, might selectively promote PACC
tumorigenesis. On the other hand, in the presence of PAC originating from alveolar type
II cells, such agents might have a net beneficiary effect by suppressing the proliferation
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of tumorigenic cells. However, a concurrent inhibition of healthy alveolar type II cell
population could be the untoward consequence of such agents in both cases. This would
be expected to affect the normal re-epithelialization/alveolar repair and · other
physiological contributions of alveolar type II cells to the proper functioning of the lungs.
Phosphodiesterase inhibitors, such as theophylline, are the primary components in the
management of chronic pulmonary diseases such as asthma. These agents induce the
intracellular accumulation of cAMP, which is known to exert a widespread anti
inflammatory activity (Giembycz, 2000). This effect alleviates inflammation and the
subsequent

airway

dysfunction.

However,

m

the

presence

of concomitant

diagnosed/undiagnosed pulmonary tumors, this effect might be detrimental by
suppressing cellular immunity against malignant cells. Since PAC diagnosis is generally
not characterized at the cellular level, the treatment of concomitant chronic respiratory
diseases should be exercised with caution. In this regard, epidemiological studies of the
association of chronic respiratory diseases and the development of lung cancer vis-a-vis
the use ofbeta-adrenergic medications is essential.

Contrary to the pattern observed in NCI-H322 cells, forskolin induced down regulation of
MAPK (ERK.1/2) activation in A549 cells. The cAMP/PKA-mediated inhibition of Raf,
which is an upstream activator of the MAPK mitogenic pathway, has been extensively
documented (Seger and Krebs, 1 995; Piiper et al., 2000). Another mechanism of MAPK
inhibition by cAMP is via cAMP/PKA-mediated inhibition of EGFR tyrosine
phosphorylation (Mitsui and Iwashita, 1 990). Immunoprecipitation and western blotting
of the EGFR following forskolin treatment showed no significant effect on receptor
1 20

tyrosine phosphorylation. Therefore, the cAMP-mediated MAPK inhibition in A549 may
be mediated by a mechanism other than inhibition of EGFR tyrosine phosphorylation.

The epidermal growth factor receptor (EGFR) plays a major role in the progression of
various types of solid tumors. Overexpression of EGFR has been found in a greater
proportion of adenocarcinomas (Rusch et al., 1993; Nakagawa 2001). This study showed
that both PAC cell types showed a low-serum induced proliferation manifested by a
marked DNA synthesis in low-serum. Western blot analysis showed that this proliferative
response was accompanied by a significant induction of MAPK activation. These
findings suggested the production of autocrine growth factor(s) in response to serum
deprivation. Pancreatic adenocarcinoma cells have been shown to proliferate indefinitely
in serum-free conditions by overexpressing the epidermal growth factor receptor and
respective ligands (Murphy et al., 2001a). Our results with interrupted cultures strongly
support this interpretation. An involvement of EGFR as a mediator of the observed low
serum-induced proliferation was supported by a significant inhibition of low-serum
induced DNA synthesis by the tyrophostin AG1478 (the EGFR-specific tyrosine kinase
inhibitor). This effect on proliferation corresponded with a significant MAPK (ERKl /2)
inhibition in a time-dependent manner.

In both cell lines, treatment with transforming growth factor alpha (TGF-a) failed to
stimulate DNA synthesis. However, the epidermal growth factor (EGF) differentially
stimulated DNA synthesis in NCI-H322. However, an antibody against EGF inhibited

121

DNA synthesis in both cell lines. A possible reason for this apparent inconsistency is that
the use of exogenous EGF might not stimulate cells that already express EGF. However,
neutralizing antibodies would be effective against endogenous growth factors released by
cells in an autocrine and/or paracrine fashion. A varying range of primary or active
ligand/s for the EGFR has been reported for the same cell line, A549 (Imanishi et al.,
1 988; Bennett, 1 999; Thrane and Schwarze, 200 1 ; Al Moustafa et al., 2002). However,
despite the diversity in the type of primary ligand/s, the EGFR appears to be the common
denominator in the proliferation of PACs. The beta-adrenergic receptor mediated
proliferation in NCI-H322 cells was completely abrogated by pretreatment with AG1478.
These findings indicate that P-adrenergic receptor stimulation transactivates the EGFR
pathway in these cells. G-protein coupled-receptor (GPCR) mediated cell proliferation
via the transactivation of the receptor tyrosine kinases has recently been shown in
fibroblasts (Maudsley et al., 2000; Luttrell et al., 1 999; Faure et al., 1 994). Therapeutic
targeting of the EGFR-mediated proliferative pathway showed promising results in early
clinical trials of non-small cell lung cancer (Arteaga et al., 2002; de Bono and Rowinsky
2002; BASELGA 200 1 ; Slichenmyer and Fry 200 1). However, for the subpopulation of
PACC, beta blockers which inhibit EGFR transactivation as well as cAMP-activation,
may be more effective.

In summary, the two cell lines derived from phenotypically different PAC cells showed
differential growth responses to beta-adrenergic agonists and elevated cAMP. However, a
similar study with a larger number of cell lines might be necessary to arrive at a more
1 22

meaningful comparison between the two phenotypes. Nonetheless, based on earlier
findings in both cell lines and related mouse cell lines, the current study points to an
essential difference in growth signaling regulation of these PAC phenotypes. Equally
important, it showed that PAC constitutes cell lines that are different not only in
morphological and histochemical characteristics, but also in their growth regulatory
pathways. Such differences preclude a blanket-type chemoprevention approach.

A

complete understanding of mitogenic signaling mechanisms is vital to the study of
pathophysiology of tumorigenesis, which is a critical step in rational chemopreventive
approaches. Care should be exercised when cancer chemoprevention is based on invitro
or laboratory animal cancer models that represent a specific signal trasduction pathway.
The unsuccessful and even tragic outcomes of carotene-retinal chemoprevention trials
(Omenn et al., 1 996) underscore the importance of characterizing the regulatory
pathways involved in the various cancer cell types. Carotene and retinals, which increase
intracellular cAMP (Prasad et al., 1 994) have significant chemoprevention activity in
hamster tracheobronchial squamous cell carcinoma (Newton et al., 1 980; Furukawa et al.,
1 999). Interestingly, epidemiological data showed that dietary beta-carotene is associated
with reduced lung cancer risk in non-smoking individuals (Mayne et al., 1 994). Such
agents also have been shown, in this and earlier studies, to function as promoters of
tumorigenesis in PAC of human and hamster models (Park et al., 1 995; Schuller et al.,
2000). Recently, Massaro and Massaro (2000) and Mao et al. (2002) reported a potential
mechanism and role of retinoids in the treatment of pulmonary emphysema, a condition
highly associated with smoking (Petty, 2002; Seagrave, 2000). Consequently, the use of
agents, such as retinals, for the treatment of smoking-induced emphysema might
123

potentially contribute to the development of P ACC by promoting tumor progression that
might have been initiated by the cigarette specific carcinogen, NNK. In fact, a significant
association between previous lung diseases, particularly emphysema, and lung cancer has
been reported recently (Brownson and Alavanja 2000).

Amidst the apparently complicated growth-signaling network, common and key elements
such as the EGFR, Raf and MAPK represent convergence points that may provide
effective pharmacological targets for a broader family of cancer types and phenotypes.
Therefore, signaling complexity could paradoxically offer practical simplicity, hence
unique opportunities for safer and more effective interventions.
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